Original Article
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
N Engl J Med 2009; 361:2209-2220December 3, 2009DOI: 10.1056/NEJMoa0908492
- Abstract
Background
The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control.
Methods
In a community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial, we evaluated four priming injections of a recombinant canarypox vector vaccine (ALVAC-HIV [vCP1521]) plus two booster injections of a recombinant glycoprotein 120 subunit vaccine (AIDSVAX B/E). The vaccine and placebo injections were administered to 16,402 healthy men and women between the ages of 18 and 30 years in Rayong and Chon Buri provinces in Thailand. The volunteers, primarily at heterosexual risk for HIV infection, were monitored for the coprimary end points: HIV-1 infection and early HIV-1 viremia, at the end of the 6-month vaccination series and every 6 months thereafter for 3 years.
Results
In the intention-to-treat analysis involving 16,402 subjects, there was a trend toward the prevention of HIV-1 infection among the vaccine recipients, with a vaccine efficacy of 26.4% (95% confidence interval [CI], −4.0 to 47.9; P=0.08). In the per-protocol analysis involving 12,542 subjects, the vaccine efficacy was 26.2% (95% CI, −13.3 to 51.9; P=0.16). In the modified intention-to-treat analysis involving 16,395 subjects (with the exclusion of 7 subjects who were found to have had HIV-1 infection at baseline), the vaccine efficacy was 31.2% (95% CI, 1.1 to 52.1; P=0.04). Vaccination did not affect the degree of viremia or the CD4+ T-cell count in subjects in whom HIV-1 infection was subsequently diagnosed.
Conclusions
This ALVAC-HIV and AIDSVAX B/E vaccine regimen may reduce the risk of HIV infection in a community-based population with largely heterosexual risk. Vaccination did not affect the viral load or CD4+ count in subjects with HIV infection. Although the results show only a modest benefit, they offer insight for future research. (ClinicalTrials.gov number, NCT00223080.)
Media in This Article
Figure 1
Enrollment and Outcomes.Figure 2
Kaplan–Meier Cumulative Rates of Infection, According to Type of Analysis.Article Activity
- Article
In the late 1980s in Thailand, there was a dramatic increase in the prevalence of infection with the human immunodeficiency virus type 1 (HIV-1) in sentinel surveillance cohorts.1-3 Initially, these groups consisted of injection-drug users and commercial sex workers; they were subsequently expanded to include persons in the general population. By 1995, the overall seroprevalence of HIV-1 reached a peak of 3.7% among conscripts in the Royal Thai Army and of 12.5% among conscripts from Northern Thailand.2,4,5 The Thai Ministry of Public Health responded with an effective HIV-prevention campaign, and the number of new HIV-1 infections per year decreased from an estimated 143,000 in 1990 to 14,000 in 2007.2,4,6-9 The persistence of new infection despite these measures led public health officials to conclude that an HIV vaccine, within the context of a broader HIV-prevention program, was needed for better control of the epidemic.
A number of trials of various subtype B canarypox–HIV vector primes and boosters containing subunit glycoprotein 120 or 160 (gp120 or gp160) established the prime–boost concept as a candidate for advanced testing.10-13 Canarypox-based prime–boost regimens induced both cellular and humoral responses, but CD8+ responses on enzyme-linked immunosorbent spot (ELISPOT) assay were low,12 and the presence of primary isolate neutralizing antibody was not consistently detected.14-18
A series of phase 1 and 2 trials of HIV vaccines involving more than 1000 Thai volunteers was undertaken, with products matching the circulating HIV-1 subtypes B and CRF01_AE.8,17-22 Although a phase 3 trial of VaxGen bivalent gp120 AIDSVAX B/E vaccine alone involving injection-drug users showed no effect on HIV-1 acquisition,21 a phase 2 trial of an ALVAC-HIV (vCP1521) prime with an AIDSVAX B/E boost showed induction of prespecified cellular and humoral immune responses and was consistent with criteria for advancement to a large test-of-concept study.17 In October 2003, our study was initiated in a population at community risk for HIV infection.8
Methods
Study Design and Population
This study was a community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial of the prime–boost combination of vaccines containing ALVAC-HIV (vCP1521) (Sanofi Pasteur) and AIDSVAX B/E (Global Solutions for Infectious Diseases). For details regarding the vaccines and placebo, see the Supplementary Appendix, available with the full text of this article at NEJM.org. The study was designed to evaluate two coprimary end points: the prevention of HIV-1 infection and the effect of vaccination on the early viral load after infection. The trial was conducted through facilities of the Thai Ministry of Public Health in Rayong and Chon Buri provinces. From September 2003 through December 2005, a total of 16,402 volunteers were enrolled.
Thai men and women who were between the ages of 18 and 30 years and who were not infected with HIV were recruited from the community without regard to HIV risk (i.e., community risk). Written informed consent was obtained from all volunteers, who were required to pass a written test of understanding. Women were counseled to practice effective contraception until 3 months after the last vaccination; pregnant and breast-feeding women were excluded.
Study Oversight
The protocol was reviewed by the ethics committees of the Ministry of Public Health, the Royal Thai Army, Mahidol University, and the Human Subjects Research Review Board of the U.S. Army Medical Research and Materiel Command. It was also independently reviewed and endorsed by the World Health Organization and the Joint United Nations Program on HIV/AIDS and by the AIDS Vaccine Research Working Group of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. The manufacturers were full trial collaborators and were a part of the phase 3 trial steering committee.
Study Procedures
The study vaccines were administered at baseline (day 0), 4 weeks (prespecified range, 3 to 7), 12 weeks (range, 10 to 15), and 24 weeks (range, 21 to 28). The ALVAC-HIV (vCP1521) vaccine was administered at each of the four visits. Boosting with AIDSVAX B/E occurred at weeks 12 and 24. For 3 days after each dose of vaccine, subjects reported local and systemic vaccine reactions on a diary card. All other adverse and serious adverse events were documented at each visit and were graded on a scale that is used for rating adverse events associated with vaccines, as recommended by the Division of Acquired Immunodeficiency Syndrome of the National Institute of Allergy and Infectious Diseases (http://rcc.tech-res.com/safetyandpharmacovigilance). All subjects who underwent randomization were included in the safety analysis.
Women underwent urine testing for pregnancy throughout the vaccination phase. Pregnant volunteers did not receive further vaccinations. All volunteers were followed with the use of HIV testing at day 0, at 24 and 26 weeks, and every 6 months during the 3-year follow-up phase. Peripheral-blood mononuclear cells were isolated and archived in liquid nitrogen at 0, 6, 12, and 42 months. Assessment of behavior associated with an increased risk of HIV infection occurred at baseline, at week 26, and at each 6-month follow-up visit. HIV-prevention counseling was provided during each vaccination and post-test counseling visit.
Primary End Points
We established the presence of HIV infection on the basis of repeated positive results on enzyme immunoassay and Western blotting, with two confirmatory HIV nucleic acid tests: the Amplicor HIV Monitor (version 1.5) assay (Roche) in Thailand and the Procleix HIV discriminatory assay (Novartis) in the United States. We performed three measurements of HIV-1 RNA within 6 weeks after serodiagnosis to determine the mean postinfection viral load. Infection time was defined as the midpoint between the last negative result and the first positive result of testing. An independent end-points monitoring committee whose members were unaware of study-group assignments verified the accuracy of all diagnoses.
Assessment of Risk
We assessed subjects' risk of HIV infection using a self-administered behavioral questionnaire at baseline and every 6 months thereafter. First, volunteers categorized themselves as being at high, moderate, or low risk for HIV infection. A second approach categorized subjects as being at high risk if they reported being at high risk or reported any high-risk behavior (e.g., needle sharing, multiple sex partners, commercial sex work, and symptoms of sexually transmitted disease). Volunteers were considered to be at low risk if they perceived their risk as low; if they reported that in the previous 6 months they had had no more than one sex partner and no sexual contact with a commercial sex worker, a partner of the same sex, an HIV-infected partner, a partner who used injection drugs, or a partner who had multiple partners; and if they reported having had no symptoms of a sexually transmitted disease or incarceration within 6 months before study entry. Moderate-risk subjects were considered to be at neither low nor high risk.
Immunogenicity Analyses
We analyzed plasma and cells from volunteers who did not have HIV infection at various time points after vaccination to evaluate immunogenicity. After removal of a small subgroup of samples for future matched case–control studies, we identified random samples and provided them in a blinded fashion to the Armed Forces Research Institute of Medical Sciences laboratory at a ratio of samples from the vaccine group to samples from the placebo group of approximately 4:1. The immunogenicity of the vaccine regimen was measured with the use of the following validated assays: interferon-γ ELISPOT and CD4+ and CD8+ intracellular cytokine staining for interferon-γ and interleukin-2 to Gag and Env; binding antibody to gp120 in the MN strain, gp120 in the A244 strain (CM244), and p24 Gag; and lymphoproliferation to gp120 MN, gp120 A244, and p24 (for details, see the Supplementary Appendix).17,18,22-25
Statistical Analysis
According to the study protocol, we conducted both intention-to-treat and per-protocol analyses. The intention-to-treat analysis included all subjects who underwent randomization. Because of the time between screening and vaccination and the possibility of acquiring HIV-1 infection during this interval, the protocol specified look-back testing of baseline plasma for HIV-1 RNA if the sample that was collected on the day of the fourth vaccination was HIV-seropositive. Seven persons who were enrolled and vaccinated were found to be positive for HIV-1 RNA at baseline. The per-protocol analysis included a subgroup of subjects in the intention-to-treat analysis who received the entire series of vaccinations within the defined time period, who remained eligible to participate in the study, and who did not have HIV infection at the time of the fourth vaccination. A separate subgroup analysis, called the modified intention-to-treat analysis, excluded the seven volunteers who were found to have HIV infection at baseline. This was used as the primary analysis at the time of the interim and final analyses and was prespecified in the final data-analysis plan that was approved 5 months before the unblinding of the study. (For details regarding the sample size calculation, randomization procedures, and calculation of vaccine efficacy, see the Supplementary Appendix.)
After the initiation of the trial, the effect of vaccination on early viral load was included as a coprimary end point, and the mean postinfection viral load was compared between vaccine and placebo recipients at the 1% level with the Wilcoxon statistic. The effect of selection bias was considered.26
The trial was monitored by an independent, international data and safety monitoring board, which met every 6 to 12 months (eight times during the trial) and reviewed the trial for safety and futility. At the interim analysis, the trial was reviewed for efficacy, safety, and futility. Statistical futility for the acquisition end point was examined with a trigger for early termination if the conditional power was less than 10%. All reported P values are two-tailed and have not been adjusted for multiple testing. A P value of less than 0.05 was considered to indicate statistical significance.
Results
Study Population
A total of 26,676 volunteers were screened and 16,402 were enrolled (intention-to-treat group) (Figure 1Figure 1
Enrollment and Outcomes.). The 12,542 subjects who completed all vaccination visits on schedule and were not found to have HIV-1 infection after receiving the full vaccination regimen were included in the per-protocol analysis. Seven volunteers who were found to be seropositive for HIV-1 on the first test after vaccination were determined by RNA testing to have been infected at enrollment and were not included in the modified intention-to-treat analysis, leaving 16,395 volunteers: 8197 in the vaccine group and 8198 in the placebo group. This group consisted of 10,064 men (61.4% of the subjects) and 6331 women (38.6%). Baseline characteristics were similar for selected variables, and there was no imbalance between the two groups in self-described risk behavior (Table 1Table 1
Baseline Characteristics of the Subjects (Modified Intention-to-Treat Population).).There were no substantive changes in serial self-reports of risk behavior during the trial. No data were collected on the status of male circumcision or on serologic analyses for adenovirus type 5 or herpes simplex virus type 2.
There were 52,985 person-years of follow-up (15% more than planned). At 42 months, 14,672 of the volunteers (89.5%) had completed the trial and were HIV-seronegative.
Adverse Events
Most local and systemic reactions to the vaccine were mild to moderate and reflected the findings of studies on the safety of these products that have been reported previously12,17,27-29 (Fig. 1 in the Supplementary Appendix). Most reactions were mild to moderate and resolved within 3 days after vaccination. At least one adverse event was reported in 69.4% of subjects in the two study groups. The number of deaths and the frequency and severity of adverse events and serious adverse events were similar in the two groups (Table 1 in the Supplementary Appendix).
Primary End Points
HIV-1 Infection
HIV-1 infection was diagnosed in 132 subjects (56 in the vaccine group and 76 in the placebo group) during 52,985 person-years of follow-up in the intention-to-treat analysis, in 86 subjects (36 in the vaccine group and 50 in the placebo group) during 36,720 person-years of follow-up in the per-protocol analysis, and in 125 subjects (51 in the vaccine group and 74 in the placebo group) during 52,985 person-years of follow-up in the modified intention-to-treat analysis. One subject in the placebo group who was identified by hospital record as being seropositive for HIV after dying from Pneumocystis jirovecii pneumonia was included in the analysis before the unblinding of the study. This diagnosis of HIV-1 infection was the only one that occurred outside planned procedures.
With the use of the Cox proportional-hazards method, the observed vaccine efficacy was 26.4% (95% confidence interval [CI], −4.0 to 47.9; P=0.08) in the intention-to-treat analysis (Figure 2AFigure 2
Kaplan–Meier Cumulative Rates of Infection, According to Type of Analysis.); 26.2% (95% CI, −13.3 to 51.9; P=0.16) in the per-protocol analysis (Figure 2B); and 31.2% (95% CI, 1.1 to 52.1; P=0.04 by the O'Brien–Fleming method) in the modified intention-to-treat analysis (Figure 2C). Because HIV testing was done at week 24, it is not possible to discern which dose of vaccine might have been associated with an early effect. The overall observed effect in the modified intention-to-treat analysis was evaluated with the use of several different analyses: event rates by Barnard's test (P=0.04), the log-rank test (P=0.04), the Wilcoxon test (P=0.03), modification of the time-to-seroconversion end point (P=0.04), exclusion of the in-hospital diagnosed case (P=0.05), and analysis of interval-censored data (P=0.04).Covariates were analyzed for the populations with similar results. Simultaneous adjustment for sex, age, living with a partner, and baseline risk factors did not affect estimates of vaccine efficacy, even though between-group differences in age, living with a partner, and baseline risk factors were significant. Subgroup analyses revealed no significant heterogeneity in vaccine efficacy according to baseline variables (Table 2Table 2
Rate of HIV Infection and Vaccine Efficacy, According to Selected Baseline Variables (Modified Intention-to-Treat Population).).There were 86 HIV-1 infections in the per-protocol population and 125 infections in the modified intention-to-treat population. There were three categories into which the 39 subjects with HIV-1 infection who were excluded from the per-protocol population could be organized: 10 subjects (3 in the vaccine group and 7 in the placebo group) were infected during the vaccination phase and received all vaccinations on schedule; 10 subjects (3 in the vaccine group and 7 in the placebo group) were infected after the vaccination phase and received all vaccinations, but one or more vaccinations were not administered during the prespecified window; and 19 subjects (9 in the vaccine group and 10 in the placebo group) were infected after the vaccination phase but did not receive all vaccinations.
Postinfection Viral Load and CD4+ T-Cell Count
There was no significant difference in the mean viral load among subjects who were found to have HIV infection in the vaccine group, as compared with those in the placebo group. The mean viral-load values were 4.36 log10 copies per milliliter in the vaccine group and 4.21 log10 copies per milliliter in the placebo group (P=0.09 by the Wilcoxon test) in the intention-to-treat analysis (Figure 3Figure 3
Viral Loads in Subjects with Early HIV-1 Infection.). The viral-load values were 4.24 log10 copies per milliliter in the vaccine group and 4.19 log10 copies per milliliter in the placebo group in the per-protocol analysis (P=0.47) and 4.30 log10 copies per milliliter and 4.20 log10 copies per milliliter, respectively, in the modified intention-to-treat analysis (P=0.24).In all three analyses, there were no significant between-group differences in postinfection CD4+ T-cell counts. The mean early postinfection CD4+ T-cell count was 541 cells per microliter in the vaccine group and 568 cells per microliter in the placebo group in the intention-to-treat analysis (P=0.47 by the Wilcoxon test), 572 cells per microliter in the vaccine group and 532 cells per microliter in the placebo group in the per-protocol analysis (P=0.72), and 555 cells per microliter in the vaccine group and 568 cells per microliter in the placebo group in the modified intention-to-treat analysis (P=0.76).
Immunogenicity
Vaccination induced an HIV-specific response, as measured by the production of interferon-γ by T cells when exposed to either Env or Gag antigen on ELISPOT assay, in 19.7% of volunteers 6 months after the final dose of vaccine was administered (Table 3Table 3
Immunogenicity Analyses at Baseline and 12 Months. and the Supplementary Appendix). This result was similar to the rate of 17% in the phase 2 trial (de Souza MS: personal communication). Response rates for CD4+ Env-specific intracellular cytokine staining were higher in the vaccine group than in the placebo group. Rates of positivity in the gp120 and p24 binding-antibody assays and the lymphoproliferation assay were similar to those in the phase 2 study.17 Binding antibody for Env was nearly uniformly present, with the reciprocal of the geometric mean titer (GMT−1) of 31,207 for the MN strain and 14,558 for the A244 strain, whereas p24 responses were less frequent (GMT−1, 138) (for details, see the Supplementary Appendix). The median lymphocyte stimulation index (LSI) was 2 for all subjects at baseline and subsequently in placebo recipients. The LSI was significantly higher in vaccine recipients (median LSI, 24 for gp120 MN, 32 for A244, and 4 for p24).Discussion
In this clinical trial, we evaluated the efficacy of ALVAC-HIV priming and AIDSVAX B/E boosting for the prevention of HIV-1 infection in more than 16,000 young Thai adults at community risk for such infection. In the intention-to-treat group (which included seven subjects who were found to have had HIV-1 infection at baseline), there was a trend toward prevention of infection with the vaccine regimen. In the per-protocol analysis, which excluded 30% of the end points and person-years of follow-up, the results were not significant. However, after the exclusion of the subjects who were infected with HIV-1 before vaccination, the modified intention-to-treat analysis showed a significant, though modest, reduction in the rate of HIV-1 infection, as compared with placebo.
Taken together, these data are consistent with a modest protective effect of vaccine in this study. However, there was no significant difference in the HIV-1 viral load or the postinfection CD4+ count between the two study groups. A simple, combined analysis of phase 1 and 2 ALVAC-HIV and gp120 prime–boost studies showed a rate of HIV-1 infection of 0.59 per 100 person-years in the vaccine group and 1.2 per 100 person-years in the placebo group, for a vaccine efficacy of 50% (95% CI, −39 to 80), a difference that was not significant; the results also showed no effect on viral load.30 In nonhuman primates, ALVAC-SIV appeared to protect neonatal macaques against infection from milk containing a low dose of simian immunodeficiency virus (SIV).31 However, ALVAC-SIV did not prevent infection from a more intense challenge exposure, although it did reduce the viral load and delay disease progression.32,33
Our trial did not have sufficient power to determine whether there was an effect of risk stratification on either disease acquisition or vaccine efficacy, and none of the observed heterogeneity achieved significance. Previous efficacy trials of HIV vaccines in higher-risk populations have not shown an effect on disease acquisition. Bivalent subtype B AIDSVAX B/B gp120 did not protect high-risk men who have sex with men,34-36 and AIDSVAX B/E did not protect Thai injection-drug users21 from infection with HIV-1. The Step trial of Merck recombinant adenovirus type 5 (rAd5) HIV-1 vaccine containing subtype B gag, pol, and nef in high-risk men who have sex with men was stopped because of futility and possibly higher rates of infection in vaccine recipients.37
An immunologic correlate with protection from HIV-1 infection has not been determined at this time. Though early studies of canarypox–gp120 subunit prime–boost regimens were promising,10-13 advanced-phase testing of subtype B ALVAC-HIV (vCP1452) and AIDSVAX B/B was canceled because CD8+ reactivity on ELISPOT was too low.12 The vaccines that were used in our trial showed a level of immunogenicity that was similar to levels reported previously.17 Additional studies with the use of more recently developed immunogenicity assays are planned in order to determine their suitability for correlates analyses.38-41 Further insight may be gained through molecular-sieve analysis of breakthrough infections with the use of single-genome amplification.42
Although our study provided preliminary evidence that an HIV vaccine regimen has the potential to prevent infection, it did not have the power to address two intriguing considerations: vaccine efficacy may have decreased over the first year after vaccination, and vaccine efficacy may have been greater in persons at lower risk for infection (Figure 2 and Table 2). These issues deserve greater attention in future studies. We do not understand the immune mechanisms mediating the results that we observed. The ALVAC-HIV and AIDSVAX B/E prime–boost regimen induces a broad constellation of immune responses against HIV-1, including T-cell–line adapted neutralizing antibody (71% with response), antibody-directed, cell-mediated cytotoxicity, CD4+ lymphoproliferation (61% with response to gp20 MN, 63% with response to gp120 CM244), and CD8+ T cells (24% with response to 51Cr-release cytotoxic T-cell assay; 17% with positive response on ELISPOT),17,33,43 but these may not be the relevant responses. Understanding the potential immunologic correlates of protection will be a principal research focus. The data also do not answer the related question of whether it was a single vaccine or the combination of vaccines that induced a potentially protective immune response. Previous studies have suggested that prime–boost combinations induce qualitative or quantitative protective immune responses that are not seen with either vaccine alone, but the current data do not address this question.28,44
Finally, our study supports the possibility that immunologic mechanisms mediating protection against HIV may be different from those mediating early postinfection control of viral replication.45,46 Taken together, these considerations underscore the opportunities afforded by the efficacy testing of HIV vaccines in human subjects in providing an objective context for review of existing methods of vaccine design, immunogenicity testing, and animal models.
Supported in part by an Interagency Agreement (Y1-AI-2642-12) between the U.S. Army Medical Research and Materiel Command and the National Institute of Allergy and Infectious Diseases and by a cooperative agreement (W81XWH-07-2-0067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine and the U.S. Department of Defense. Sanofi Pasteur provided the ALVAC-HIV vaccine, and Global Solutions for Infectious Diseases (VaxGen) provided the reagents for the immunogenicity assays.
The opinions expressed in this article are those of the authors and do not represent the official views of the Department of Health and Human Services, the National Institute of Allergy and Infectious Diseases, the Centers for Disease Control and Prevention, the Department of Defense, or Department of the Army.
Drs. Gurunathan, Tartaglia, and McNeil report being employees of Sanofi Pasteur, and Dr. Tartaglia reports having an equity interest in the company. No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0908492) was published on October 20, 2009, and was last updated on November 19, 2009, at NEJM.org.
We thank the volunteers who participated in this study and staff members of the Ministry of Public Health at health centers in Rayong, Chon Buri, and surrounding provinces.
Source Information
From the Department of Disease Control, Ministry of Public Health, Nonthaburi (S.R.-N., R.P., C.N., S.C., C.K., P.T., P.K.); Vaccine Trials Center (P.P.) and Data Management Unit (J.K.), Faculty of Tropical Medicine, Mahidol University, Bangkok; Thai Component (S.N.) and U.S. Army Medical Component (J.C., R.P., M.S., M.B.), Armed Forces Research Institute of Medical Sciences, Bangkok — all in Thailand; the Division of AIDS, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD (E.A.); Sanofi Pasteur, Swiftwater, PA (S.G., J.T., J.G.M.); Global Solutions for Infectious Diseases, South San Francisco, CA (D.P.F.); the Emmes Corporation, Rockville, MD (D.S.); the Global AIDS Program, Centers for Disease Control and Prevention, Atlanta (D.L.B.); U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Rockville, MD (M.L.R., N.L.M., J.H.K.); and U.S. Army Medical Materiel Development Activity, Ft. Detrick, MD (J.H.K.).
Address reprint requests to Dr. Kim at the U.S. Military HIV Research Program, Walter Reed Army Institute of Research, 1600 E. Gude Dr., Rockville, MD 20850, or at jkim@hivresearch.org.
The names and affiliations of the Ministry of Public Health–Thai AIDS Vaccine Evaluation Group (MOPH–TAVEG) investigators are listed in the Appendix.
Appendix
The following investigators and institutions participated in the MOPH-TAVEG study: Ministry of Public Health, Thailand: S. Rerks-Ngarm, S. Chunsuttiwat, N. Premsri, C. Namwat, P. Kunasol, P. Thongcharoen, C. Khamboonruang; Vaccine Trials Center, Mahidol University: P. Pitisuttithum, V. Bussaratid, W. Maek-a-nantawat, J. Dhitavat, P. Suntharasamai, S. Pungpak, S. Vanijanonta; Data Management Unit, Mahidol University: J. Kaewkunwal, A. Khamsiriwatchara, P. Jarujareet; Royal Thai Army, Armed Forces Research Institute of Medical Sciences: S. Nitayaphan, C. Easmila, S. Tabprasit; U.S. Army Component, Armed Forces Research Institute of Medical Sciences: J. Chiu, R. Paris, M. Benenson, A. Brown, P. Morgan, M. de Souza, R. Trichavaroj, A. Schuetz, N. Thaitawat; Sanofi Pasteur: S. Gurunathan, J. Tartaglia, J.G. McNeil, R. Harkness, C. Meric, R. El Habib, L. Baglyos; Global Solutions in Infectious Diseases: D. Francis, C. Lee; National Institute of Allergy and Infectious Diseases: E. Adams; U.S. Military HIV Research Program, Walter Reed Army Institute of Research and U.S. Army Medical Materiel Development Agency, U.S. Army Medical Research and Materiel Command: J.H. Kim, M.L. Robb, N.L. Michael, M. Milazzo, A. Bolen, B. Wessner, S.R. Kim, M. Marovich, J. Currier; Global AIDS Program, Centers for Disease Control and Prevention: D.L. Birx; Emmes Corporation: D. Stablein, T. Germanson, L. Dally; SHI Consulting: R. Wiley; International AIDS Vaccine Initiative: Dr. J.-L. Excler; Tripler Army Medical Center: Dr. J. Berenberg.
- References
References
1
Brown T ,Peerapatanapokin W . The Asian epidemic model: a process model for exploring HIV policy and programme alternatives in Asia. Sex Transm Infect 2004;80:Suppl 1:i19-i24
CrossRef | Web of Science | Medline2
Phoolcharoen W . HIV/AIDS prevention in Thailand: success and challenges. Science 1998;280:1873-1874
CrossRef | Web of Science | Medline3
Weniger BG ,Limpakarnjanarat K ,Ungchusak K , et al. The epidemiology of HIV infection and AIDS in Thailand. AIDS 1991;5:S71-S85[Erratum, AIDS 1993;7:following 147.]
CrossRef | Medline4
Nelson KE ,Celentano DD ,Eiumtrakol S , et al. Changes in sexual behavior and a decline in HIV infection among young men in Thailand. N Engl J Med 1996;335:297-303
Free Full Text | Web of Science | Medline5
Nitayaphan S ,Brown AE . Preventive HIV vaccine development in Thailand. AIDS1998;S155-S161
Medline6
Hanenberg RS ,Rojanapithayakorn W ,Kunasol P ,Sokal DC . Impact of Thailand's HIV-control programme as indicated by the decline of sexually transmitted diseases. Lancet 1994;344:243-245
CrossRef | Web of Science | Medline7
Nelson KE ,Celentano DD ,Suprasert S , et al. Risk factors for HIV infection among young adult men in northern Thailand. JAMA 1993;270:955-960
CrossRef | Web of Science | Medline8
Rerks-Ngarm S ,Brown AE ,Khamboonruang C ,Thongcharoen P ,Kunasol P . HIV/AIDS preventive vaccine `prime-boost' phase III trial: foundations and initial lessons learned from Thailand. AIDS 2006;20:1471-1479
CrossRef | Web of Science | Medline9
National AIDS Prevention and Alleviation Committee. UNGASS country progress report: Thailand. Reporting Period January 2006 - December 2007. (Accessed October 19, 2009, at http://data.unaids.org/pub/Report/2008/thailand_2008_country_progress_report_en.pdf.)
10
Belshe RB ,Gorse GJ ,Mulligan MJ , et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 1998;12:2407-2415
CrossRef | Web of Science | Medline11
Belshe RB ,Graham BS ,Keefer MC , et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 1994;272:475-480
CrossRef | Web of Science | Medline12
Russell ND ,Graham BS ,Keefer MC , et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 2007;44:203-212
CrossRef | Web of Science | Medline13
The AIDS Vaccine Evaluation Group 022 Protocol Team
CrossRef | Medline14
Mascola JR ,Snyder SW ,Weislow OS , et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996;173:340-348
CrossRef | Web of Science | Medline15
Verrier F ,Burda S ,Belshe R , et al. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show intercalde cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates. J Virol 2000;74:10025-10033
CrossRef | Web of Science | Medline16
Zolla-Pazner S ,Xu S ,Burda S ,Duliege AM ,Excler JL ,Clements-Mann ML . Neutralization of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HIV)-uninfected recipients of candidate HIV vaccines. J Infect Dis 1998;178:1502-1506
CrossRef | Web of Science | Medline17
Nitayaphan S ,Pitisuttithum P ,Karnasuta C , et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 2004;190:702-706
CrossRef | Web of Science | Medline18
Thongcharoen P ,Suriyanon V ,Paris RM , et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007;46:48-55
CrossRef | Web of Science | Medline19
Nitayaphan S ,Khamboonruang C ,Sirisophana N , et al. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. Vaccine 2000;18:1448-1455
CrossRef | Web of Science | Medline20
Pitisuttithum P ,Berman PW ,Phonrat B , et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J Acquir Immune Defic Syndr 2004;37:1160-1165[Erratum, J Acquir Immune Defic Syndr 2004;37:1669.]
CrossRef | Web of Science | Medline21
Pitisuttithum P ,Gilbert P ,Gurwith M , et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006;194:1661-1671
CrossRef | Web of Science | Medline22
Pitisuttithum P ,Nitayaphan S ,Thongcharoen P , et al. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J Infect Dis 2003;188:219-227
CrossRef | Web of Science | Medline23
Kibuuka H, Kimutai R, Maboko L, et al. A phase I/II study of a multiclade HIV-1 DNA plasmid prime and recombinant Adenovirus-type 5 boost vaccine in HIV uninfected East Africans. J Infect Dis (in press).
24
Currier JR ,Kuta EG ,Turk E , et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002;260:157-172
CrossRef | Web of Science | Medline25
Fu TM ,Dubey SA ,Mehrotra DV , et al. Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. AIDS Res Hum Retroviruses 2007;23:67-76
CrossRef | Web of Science | Medline26
Gilbert PB ,Bosch RJ ,Hudgens MG . Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials. Biometrics 2003;59:531-541
CrossRef | Web of Science | Medline27
Belshe RB ,Stevens C ,Gorse GJ , et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001;183:1343-1352
CrossRef | Web of Science | Medline28
Clements-Mann ML ,Weinhold K ,Matthews TJ , et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998;177:1230-1246
CrossRef | Web of Science | Medline29
Gupta K ,Hudgens M ,Corey L , et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 2002;29:254-261
Web of Science | Medline30
Lee D ,Graham BS ,Chiu YL , et al. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis 2004;190:903-907
CrossRef | Web of Science | Medline31
Van Rompay KK ,Abel K ,Lawson JR , et al. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr 2005;38:124-134
CrossRef | Web of Science | Medline32
Pal R ,Venzon D ,Letvin NL , et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol 2002;76:292-302
CrossRef | Web of Science | Medline33
Pal R ,Venzon D ,Santra S , et al. Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J Virol 2006;80:3732-3742
CrossRef | Web of Science | Medline34
Gilbert PB ,Ackers ML ,Berman PW , et al. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis 2005;192:974-983
CrossRef | Web of Science | Medline35
Gilbert PB ,Peterson ML ,Follmann D , et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005;191:666-677
CrossRef | Web of Science | Medline36
Flynn NM ,Forthal DN ,Harro CD ,Judson FN ,Mayer KH ,Para MF . Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191:654-665
CrossRef | Web of Science | Medline37
Buchbinder SP ,Mehrotra DV ,Duerr A , et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-1893
CrossRef | Web of Science | Medline38
Mascola JR ,D'Souza P ,Gilbert P , et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 2005;79:10103-10107
CrossRef | Web of Science | Medline39
Forthal DN ,Gilbert PB ,Landucci G ,Phan T . Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007;178:6596-6603
Web of Science | Medline40
McElrath MJ ,De Rosa SC ,Moodie Z , et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008;372:1894-1905
CrossRef | Web of Science | Medline41
Seder RA ,Darrah PA ,Roederer M . T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008;8:247-258[Erratum, Nat Rev Immunol 2008;8:486.]
CrossRef | Web of Science | Medline42
Salazar-Gonzalez JF ,Salazar MG ,Keele BF , et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009;206:1273-1289
CrossRef | Web of Science | Medline43
Karnasuta C ,Paris RM ,Cox JH , et al. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005;23:2522-2529
CrossRef | Web of Science | Medline44
Ratto-Kim S ,Loomis-Price LD ,Aronson N , et al. Comparison between env-specific T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV(vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults. J Acquir Immune Defic Syndr 2003;32:9-17
CrossRef | Web of Science | Medline45
Alter G ,Teigen N ,Ahern R , et al. Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J Infect Dis 2007;195:1452-1460
CrossRef | Web of Science | Medline46
Goonetilleke N ,Liu MK ,Salazar-Gonzalez JF , et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009;206:1253-1272
CrossRef | Web of Science | Medline
- Citing Articles (523)
Citing Articles
1
Methods of Primary Prevention. In: Jekel's Epidemiology, Biostatistics, Preventive Medicine, and Public Health. Elsevier, 2014:181-195.
2
Yu-Qian Wang, Hai-Hong Zhang, Chen-Lu Liu, Hui Wu, Peng Wang, Qiu Xia, Li-Xing Zhang, Bo Li, Jia-Xin Wu, Bin Yu, Tie-Jun Gu, Xiang-Hui Yu, Wei Kong. (2013) Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model. International Immunopharmacology 17:1, 9-17
3
J. T. Frencher, B. K. Ryan-Pasyeur, D. Huang, R. C. Wang, P. D. McMullen, N. L. Letvin, W. E. Collins, N. E. Freitag, M. Malkovsky, C. Y. Chen, L. Shen, Z. W. Chen. (2013) SHIV Antigen Immunization Alters Patterns of Immune Responses to SHIV/Malaria Coinfection and Protects against Life-Threatening SHIV-Related Malaria. Journal of Infectious Diseases 208:2, 260-270
4
Wenjin Guo, Brad Cleveland, Thaddeus M. Davenport, Kelly K. Lee, Shiu-Lok Hu. (2013) Purification of recombinant vaccinia virus-expressed monomeric HIV-1 gp120 to apparent homogeneity. Protein Expression and Purification 90:1, 34-39
5
Barton F. Haynes, M. Juliana McElrath. (2013) Progress in HIV-1 vaccine development. Current Opinion in HIV and AIDS 8:4, 326-332
6
Jonathan D. Fuchs, Magdalena E. Sobieszczyk, Tamra Madenwald, Doug Grove, Shelly T. Karuna, Michele Andrasik, Adam Sherwat, Gail Broder, Kenneth Mayer, Beryl Koblin, Scott Hammer. (2013) Intentions to Use Preexposure Prophylaxis Among Current Phase 2B Preventive HIV-1 Vaccine Efficacy Trial Participants. JAIDS Journal of Acquired Immune Deficiency Syndromes 63:3, 259-262
7
Hong-Van Tieu, Morgane Rolland, Scott M. Hammer, Magdalena E. Sobieszczyk. (2013) Translational Research Insights From Completed HIV Vaccine Efficacy Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S150-S154
8
Wafaa M. El-Sadr, David M. Serwadda, Nirupama Sista, Myron S. Cohen. (2013) HIV Prevention. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S115-S116
9
Beryl A. Koblin, Michele Andrasik, Judy Austin. (2013) Preparing for the Unexpected. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S183-S186
10
Mitchell J. Warren, Emily S. Bass. (2013) Perspectives on HIV Prevention. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S255-S259
11
Elizabeth Miller, Nina Bhardwaj. (2013) Dendritic cell dysregulation during HIV-1 infection. Immunological Reviews 254:1, 170-189
12
John R. Mascola, Barton F. Haynes. (2013) HIV-1 neutralizing antibodies: understanding nature's pathways. Immunological Reviews 254:1, 225-244
13
Korey R. Demers, Morgan A. Reuter, Michael R. Betts. (2013) CD8 + T-cell effector function and transcriptional regulation during HIV pathogenesis. Immunological Reviews 254:1, 190-206
14
Huanbin Xu, Xiaolei Wang, Ronald S. Veazey. (2013) Mucosal immunology of HIV infection. Immunological Reviews 254:1, 10-33
15
Kathryn E. Stephenson, Dan H. Barouch. (2013) A global approach to HIV-1 vaccine development. Immunological Reviews 254:1, 295-304
16
Piot , Peter , Quinn , Thomas C. , . (2013) Response to the AIDS Pandemic — A Global Health Model. New England Journal of Medicine 368:23, 2210-2218
Free Full Text17
Jingying Zhou, Allen K.L. Cheung, Zhiwu Tan, Haibo Wang, Wenbo Yu, Yanhua Du, Yuanxi Kang, Xiaofan Lu, Li Liu, Kwok-Yung Yuen, Zhiwei Chen. (2013) PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice. Journal of Clinical Investigation 123:6, 2629-2642
18
Thorsten Demberg, Egidio Brocca-Cofano, Seraphin Kuate, Stanley Aladi, Diego A. Vargas-Inchaustegui, David Venzon, Irene Kalisz, V.S. Kalyanaraman, Eun Mi Lee, Ranajit Pal, Janet DiPasquale, Ruth M. Ruprecht, David C. Montefiori, Indresh Srivastava, Susan W. Barnett, Marjorie Robert-Guroff. (2013) Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques. Virology 440:2, 210-221
19
Sten H. Vermund, Richard J. Hayes. (2013) Combination Prevention: New Hope for Stopping the Epidemic. Current HIV/AIDS Reports 10:2, 169-186
20
Anjali Singh, Jon Warren, Alan Schultz, Charles J. Hackett, Opendra Sharma. (2013) Working Group Consultation: Alloimmunity as a Vaccine Approach Against HIV/AIDS: National Institutes of Health Meeting Report, May 24, 2012. AIDS Research and Human Retroviruses 29:6, 851-858
21
Sten H. Vermund, José A. Tique, Holly M. Cassell, Megan E. Pask, Philip J. Ciampa, Carolyn M. Audet. (2013) Translation of Biomedical Prevention Strategies for HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes 63, S12-S25
22
Renaud F Boulanger, Stephanie Seidel, Erica Lessem, Lee Pyne-Mercier, Sharon D Williams, Laia Ruiz Mingote, Cherise Scott, Alicia Y Chou, James V Lavery. (2013) Engaging communities in tuberculosis research. The Lancet Infectious Diseases 13:6, 540-545
23
Rebecca L.R. Powell, Ian Ouellette, Ross W. Lindsay, Christopher L. Parks, C. Richter King, Adrian B. McDermott, Gavin Morrow. (2013) A Multiplex Microsphere-Based Immunoassay Increases the Sensitivity of SIV-Specific Antibody Detection in Serum Samples and Mucosal Specimens Collected from Rhesus Macaques Infected with SIVmac239. BioResearch Open Access 2:3, 171-178
24
CunXia Liu, ShouWen Du, Chang Li, YuHang Wang, MaoPeng Wang, Yi Li, RongLan Yin, Xiao Li, DaYong Ren, YanQing Qin, JingQiang Ren, NingYi Jin. (2013) Immunogenicity analysis following human immunodeficiency virus recombinant DNA and recombinant vaccinia virus Tian Tan prime-boost immunization. Science China Life Sciences 56:6, 531-540
25
Simon J. Draper, Matthew G. Cottingham, Sarah C. Gilbert. (2013) Utilizing poxviral vectored vaccines for antibody induction—Progress and prospects. Vaccine
26
Greg C. Imholte, Renan Sauteraud, Bette Korber, Robert T. Bailer, Ellen T. Turk, Xiaoying Shen, Georgia D. Tomaras, John R. Mascola, Richard A. Koup, David C. Montefiori, Raphael Gottardo. (2013) A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling. Journal of Immunological Methods
27
Marc P. Girard, Valentina Picot, Christophe Longuet, Gary J. Nabel. (2013) Report of the Cent Gardes HIV Vaccine Conference: The B-cell response to HIV Part 2: Non-neutralizing antibodies. Vaccine 31:29, 2984-2987
28
V. A. Chereshnev, G. Bocharov, S. Bazhan, B. Bachmetyev, I. Gainova, V. Likhoshvai, J. M. Argilaguet, J. P. Martinez, J. A. Rump, B. Mothe, C. Brander, A. Meyerhans. (2013) Pathogenesis and Treatment of HIV Infection: The Cellular, the Immune System and the Neuroendocrine Systems Perspective. International Reviews of Immunology 32:3, 282-306
29
Michael P. Cameron, Peter A. Newman, Surachet Roungprakhon, Riccardo Scarpa. (2013) The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine. Vaccine
30
G. D. Tomaras, G. Ferrari, X. Shen, S. M. Alam, H.-X. Liao, J. Pollara, M. Bonsignori, M. A. Moody, Y. Fong, X. Chen, B. Poling, C. O. Nicholson, R. Zhang, X. Lu, R. Parks, J. Kaewkungwal, S. Nitayaphan, P. Pitisuttithum, S. Rerks-Ngarm, P. B. Gilbert, J. H. Kim, N. L. Michael, D. C. Montefiori, B. F. Haynes. (2013) Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proceedings of the National Academy of Sciences 110:22, 9019-9024
31
S. A. Plotkin. (2013) Complex Correlates of Protection After Vaccination. Clinical Infectious Diseases 56:10, 1458-1465
32
Michael Evangeli, Zuhayr Kafaar, Ashraf Kagee, Leslie Swartz, Philippa Bullemor-Day. (2013) Does message framing predict willingness to participate in a hypothetical HIV vaccine trial: An application of Prospect Theory. AIDS Care 25:7, 910-914
33
Weizao Chen, Tianlei Ying, Dimiter S Dimitrov. (2013) Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design. Expert Opinion on Biological Therapy 13:5, 657-671
34
Kenneth Kintu, Philip Andrew, Philippa Musoke, Paul Richardson, Brenda Asiimwe-Kateera, Teopista Nakyanzi, Lei Wang, Mary Glenn Fowler, Lynda Emel, San-San Ou, Lynn Baglyos, Sanjay Gurunathan, Sheryl Zwerski, Jay Brooks Jackson, Laura Guay. (2013) Feasibility and Safety of ALVAC-HIV vCP1521 Vaccine in HIV-Exposed Infants in Uganda. JAIDS Journal of Acquired Immune Deficiency Syndromes 63:1, 1-8
35
Stefan Baral, Andrew Scheibe, Patrick Sullivan, Gift Trapence, Andrew Lambert, Linda-Gail Bekker, Chris Beyrer. (2013) Assessing Priorities for Combination HIV Prevention Research for Men Who have Sex with Men (MSM) in Africa. AIDS and Behavior 17:S1, 60-69
36
Ria Lassaunière, Sharon Shalekoff, Caroline T. Tiemessen. (2013) A novel FCGR3A intragenic haplotype is associated with increased FcγRIIIa/CD16a cell surface density and population differences. Human Immunology 74:5, 627-634
37
Laura Richert, Rodolphe Thiebaut. (2013) Is the current use of ‘positivity’ thresholds meaningful for evaluating HIV-vaccine immunogenicity endpoints?. AIDS 27:8, 1362-1365
38
Margaret E. Ackerman, Max Crispin, Xiaojie Yu, Kavitha Baruah, Austin W. Boesch, David J. Harvey, Anne-Sophie Dugast, Erin L. Heizen, Altan Ercan, Ickwon Choi, Hendrik Streeck, Peter A. Nigrovic, Chris Bailey-Kellogg, Chris Scanlan, Galit Alter. (2013) Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. Journal of Clinical Investigation 123:5, 2183-2192
39
Tracey A Day, Cecilia A Morgan, James G Kublin. (2013) Will mosaic vaccine immunogens expand immune response breadth to rival HIV-1 strain diversity?. Clinical Investigation 3:5, 413-415
40
Gerhard Bauer. (2013) HIV-1 vaccine antibody induction against a variable region of HIV-1: a possible link to protective immunity?. Immunotherapy 5:5, 453-455
41
José Esparza. (2013) Progress in the development of an adenovirus 26 vector platform for HIV vaccines. Expert Review of Vaccines 12:5, 477-480
42
Matthew D. Marsden, Jerome A. Zack. (2013) HIV/AIDS eradication. Bioorganic & Medicinal Chemistry Letters
43
José Esparza. (2013) A brief history of the global effort to develop a preventive HIV vaccine. Vaccine
44
Eva Van Braeckel, Isabelle Desombere, Frédéric Clement, Linos Vandekerckhove, Chris Verhofstede, Dirk Vogelaers, Geert Leroux-Roels. (2013) Polyfunctional CD4+ T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine. Vaccine
45
Hirotaka Sato, Chen Jing, Mao Isshiki, Kazuhiro Matsuo, Minoru Kidokoro, Shiki Takamura, Xianfeng Zhang, Takashi Ohashi, Hisatoshi Shida. (2013) Immunogenicity and safety of the vaccinia virus LC16m8Δ vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol. Vaccine
46
C Moog, N Dereuddre-Bosquet, J-L Teillaud, M E Biedma, V Holl, G Van Ham, L Heyndrickx, A Van Dorsselaer, D Katinger, B Vcelar, S Zolla-Pazner, I Mangeot, C Kelly, R J Shattock, R Le Grand. (2013) Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunology
47
S. Rerks-Ngarm, R. M. Paris, S. Chunsutthiwat, N. Premsri, C. Namwat, C. Bowonwatanuwong, S. S. Li, J. Kaewkungkal, R. Trichavaroj, N. Churikanont, M. S. de Souza, C. Andrews, D. Francis, E. Adams, J. Flores, S. Gurunathan, J. Tartaglia, R. J. O'Connell, C. Eamsila, S. Nitayaphan, V. Ngauy, P. Thongcharoen, P. Kunasol, N. L. Michael, M. L. Robb, P. B. Gilbert, J. H. Kim. (2013) Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E. Journal of Infectious Diseases 207:8, 1195-1205
48
A.-L. Spetz, F. Chiodi. (2013) Reduction of HIV-1 Load in Semen During Follow-up Study of RV144 Vaccine Trial Boosts Interest for Novel Correlates of Immune Protection in Genital Mucosa. Journal of Infectious Diseases 207:8, 1189-1192
49
Lorenzo Antonio Ramirez, Tatiana Arango, Jean Boyer. (2013) Therapeutic and prophylactic DNA vaccines for HIV-1. Expert Opinion on Biological Therapy 13:4, 563-573
50
B. Lyons. (2013) Male Infant Circumcision as a 'HIV Vaccine'. Public Health Ethics 6:1, 90-103
51
Stefania Capone, Anna Morena D’Alise, Virginia Ammendola, Stefano Colloca, Riccardo Cortese, Alfredo Nicosia, Antonella Folgori. (2013) Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Review of Vaccines 12:4, 379-393
52
Simone C de Cassan, Simon J Draper. (2013) Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. Expert Review of Vaccines 12:4, 365-378
53
Lianxing Liu, Chao Qiu, Yang Huang, Jianqing Xu, Yiming Shao. (2013) Potent T cell responses induced by single DNA vaccine boosted with recombinant vaccinia vaccine. Virologica Sinica 28:2, 109-115
54
David Hallengärd, Britta Wahren, Andreas Bråve. (2013) A Truncated Plasmid-Encoded HIV-1 Reverse Transcriptase Displays Strong Immunogenicity. Viral Immunology 26:2, 163-166
55
Wayne C. Koff, Nina D. Russell, Mark Walport, Mark B. Feinberg, John W. Shiver, Salim Abdool Karim, Bruce D. Walker, Margaret G. McGlynn, Chidi Victor Nweneka, Gary J. Nabel. (2013) Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines. Vaccine 31, B204-B208
56
Virginie Supervie. (2013) Les moyens de prévention de l’infection à VIH à base d’antirétroviraux. médecine/sciences 29:4, 373-382
57
G. J. V. Nossal. (2013) Immunology and world health: key contributions from the global community. Annals of the New York Academy of Sciences 1283:1, 1-7
58
Jinyao Li, Antonio Valentin, Viraj Kulkarni, Margherita Rosati, Rachel Kelly Beach, Candido Alicea, Drew Hannaman, Steven G. Reed, Barbara K. Felber, George N. Pavlakis. (2013) HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine
59
Rob J. Center, Annett Miller, Adam K. Wheatley, Shahan M. Campbell, Carly Siebentritt, Damian F.J. Purcell. (2013) Utility of the Sindbis replicon system as an Env-targeted HIV vaccine. Vaccine 31:18, 2260-2266
60
Kalani Halemano, Michael S. Harper, Kejun Guo, Sam X. Li, Karl J. Heilman, Bradley S. Barrett, Mario L. Santiago. (2013) Humoral immunity in the Friend retrovirus infection model. Immunologic Research 55:1-3, 249-260
61
Derek R. Stein, Adam Burgener, Terry Blake Ball. (2013) Proteomics as a novel HIV immune monitoring tool. Current Opinion in HIV and AIDS 8:2, 140-146
62
W.-H. Li, C.-Y. Li, H.-B. Yang, H.-P. Zhang, X. Zhang, L.-S. Kong, X.-N. Xu, S.-C. Lu, H.-P. Yan. (2013) Human leucocyte antigen-Bw4 and Gag-specific T cell responses are associated with slow disease progression in HIV-1B-infected anti-retroviral therapy-naive Chinese. Clinical & Experimental Immunology 171:3, 298-306
63
Allan R. Tenorio, Alan L. Landay. (2013) HIV: So Near and Yet So Far. Current HIV/AIDS Reports 10:1, 1-2
64
Janet Chung, David L DiGiusto, John J Rossi. (2013) Combinatorial RNA-based gene therapy for the treatment of HIV/AIDS. Expert Opinion on Biological Therapy 13:3, 437-445
65
Marta Rodriguez-Garcia, Mickey V. Patel, Charles R. Wira. (2013) Innate and adaptive anti-HIV immune responses in the female reproductive tract. Journal of Reproductive Immunology 97:1, 74-84
66
Peter Michael Moyle, Istvan Toth. (2013) Modern Subunit Vaccines: Development, Components, and Research Opportunities. ChemMedChem 8:3, 360-376
67
Marc Gurwith, Michael Lock, Eve M Taylor, Glenn Ishioka, Jeff Alexander, Tim Mayall, John E Ervin, Richard N Greenberg, Cynthia Strout, John J Treanor, Richard Webby, Peter F Wright. (2013) Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. The Lancet Infectious Diseases 13:3, 238-250
68
Sebastian K Grimm, Margaret E Ackerman. (2013) Vaccine design: emerging concepts and renewed optimism. Current Opinion in Biotechnology
69
Kristen Underhill. (2013) Study designs for identifying risk compensation behavior among users of biomedical HIV prevention technologies: Balancing methodological rigor and research ethics. Social Science & Medicine
70
Raiees Andrabi, Constance Williams, Xiao-Hong Wang, Liuzhe Li, Alok K. Choudhary, Naveet Wig, Ashutosh Biswas, Kalpana Luthra, Arthur Nadas, Michael S. Seaman, Phillipe Nyambi, Susan Zolla-Pazner, Miroslaw K. Gorny. (2013) Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals. Virology
71
Michele D Tameris, Mark Hatherill, Bernard S Landry, Thomas J Scriba, Margaret Ann Snowden, Stephen Lockhart, Jacqueline E Shea, J Bruce McClain, Gregory D Hussey, Willem A Hanekom, Hassan Mahomed, Helen McShane. (2013) Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. The Lancet 381:9871, 1021-1028
72
Jaranit Kaewkungwal, Punnee Pitisuttithum, Supachai Rerks-ngarm, Sorachai Nitayaphan, Chirasak Khamboonruang, Prayura Kunasol, Pravan Suntharasamai, Swangjai Pungpak, Sirivan Vanijanonta, Valai Bussaratid, Wirach Maek-a-nantawat, Jittima Dhitavat, Prasert Thongcharoen, Rungrawee Pawarana, Yupa Sabmee, Mike W Benenson, Patricia Morgan, Robert J. O’ Connell, Jerome Kim. (2013) Issues in Women's Participation in a Phase III Community HIV Vaccine Trial in Thailand. AIDS Research and Human Retroviruses130225072143000
73
V. Patel, R. Jalah, V. Kulkarni, A. Valentin, M. Rosati, C. Alicea, A. von Gegerfelt, W. Huang, Y. Guan, B. F. Keele, J. W. Bess, M. Piatak, J. D. Lifson, W. T. Williams, X. Shen, G. D. Tomaras, R. R. Amara, H. L. Robinson, W. Johnson, K. E. Broderick, N. Y. Sardesai, D. J. Venzon, V. M. Hirsch, B. K. Felber, G. N. Pavlakis. (2013) DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proceedings of the National Academy of Sciences 110:8, 2975-2980
74
L. E. McCoy, R. A. Weiss. (2013) Neutralizing antibodies to HIV-1 induced by immunization. Journal of Experimental Medicine 210:2, 209-223
75
Nabel , Gary J. , . (2013) Designing Tomorrow's Vaccines. New England Journal of Medicine 368:6, 551-560
Free Full Text76
Hendrik Streeck, M Patricia D'Souza, Dan R Littman, Shane Crotty. (2013) Harnessing CD4+ T cell responses in HIV vaccine development. Nature Medicine 19:2, 143-149
77
Preston Izulla, Lyle R. McKinnon, Julius Munyao, Sarah Karanja, Winnie Koima, Joshua Parmeres, Solomon Kamuti, Rosalia Kioko, Nico Nagelkerke, Gloria Gakii, Charles Wachihi, Nicholas Muraguri, Helgar Musyoki, Lawrence Gelmon, Rupert Kaul, Joshua Kimani. (2013) HIV Postexposure Prophylaxis in an Urban Population of Female Sex Workers in Nairobi, Kenya. JAIDS Journal of Acquired Immune Deficiency Syndromes 62:2, 220-225
78
Harriet L. Robinson. (2013) Non-neutralizing antibodies in prevention of HIV infection. Expert Opinion on Biological Therapy 13:2, 197-207
79
Leia H. Wren, Amy W. Chung, Gamze Isitman, Anthony D. Kelleher, Matthew S. Parsons, Janaki Amin, David A. Cooper, , Ivan Stratov, Marjon Navis, Stephen J. Kent. (2013) Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 138:2, 116-123
80
Fernanda Heloise Côrtes, Gonzalo Bello, Carla Vorsatz, José Henrique Pilotto, Monick Lindenmeyer Guimarães, Beatriz Grinsztejn, Valdiléa Gonçalves Veloso, Aguinaldo Roberto Pinto, Mariza Gonçalves Morgado. (2013) Higher cross-subtype IFN-γ ELISpot responses to Gag and Nef peptides in Brazilian HIV-1 subtype B- and F1- than in C-infected subjects. Vaccine 31:7, 1106-1112
81
Sengeziwe Sibeko, Shokouh Makvandi-Nejad. (2013) From the Laboratory to Clinical Trials and Back Again: Lessons Learned from HIV Prevention Trials. American Journal of Reproductive Immunology 69, 106-115
82
Yuanxi Kang, Jia Guo, Zhiwei Chen. (2013) Closing the door to human immunodeficiency virus. Protein & Cell 4:2, 86-102
83
M. Juraska, P. B. Gilbert. (2013) Mark-Specific Hazard Ratio Model with Multivariate Continuous Marks: An Application to Vaccine Efficacy. Biometricsno-no
84
Laura Richert, Sophie Hue, Hakim Hocini, Mathieu Raimbault, Christine Lacabaratz, Mathieu Surenaud, Aurélie Wiedemann, Pascaline Tisserand, Christine Durier, Dominique Salmon, Jean-Daniel Lelievre, Geneviève Chêne, Rodolphe Thiebaut, Yves Levy. (2013) Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers. AIDS1
85
D. H. Barouch, J. Liu, L. Peter, P. Abbink, M. J. Iampietro, A. Cheung, G. Alter, A. Chung, A.-S. Dugast, N. Frahm, M. J. McElrath, H. Wenschuh, U. Reimer, M. S. Seaman, M. G. Pau, M. Weijtens, J. Goudsmit, S. R. Walsh, R. Dolin, L. R. Baden. (2013) Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001). Journal of Infectious Diseases 207:2, 248-256
86
L. R. Baden, S. R. Walsh, M. S. Seaman, R. P. Tucker, K. H. Krause, A. Patel, J. A. Johnson, J. Kleinjan, K. E. Yanosick, J. Perry, E. Zablowsky, P. Abbink, L. Peter, M. J. Iampietro, A. Cheung, M. G. Pau, M. Weijtens, J. Goudsmit, E. Swann, M. Wolff, H. Loblein, R. Dolin, D. H. Barouch. (2013) First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001). Journal of Infectious Diseases 207:2, 240-247
87
Mitchell J. Warren, Emily S. Bass. (2013) From Efficacy to Impact. American Journal of Preventive Medicine 44:1, S167-S170
88
H. In: Ferri's Clinical Advisor 2013. Elsevier, 2013:447-566.
89
José Esparza. (2013) A tale of two vaccines. AIDS 27:1, 1-5
90
John A. Davis. (2013) HIV and the LGBT Community: A Medical Update. Journal of Gay & Lesbian Mental Health 17:1, 64-79
91
Y. Sun, M. Li, P. B. Gilbert. (2013) Mark-specific proportional hazards model with multivariate continuous marks and its application to HIV vaccine efficacy trials. Biostatistics 14:1, 60-74
92
Hua-Xin Liao, Mattia Bonsignori, S. Munir Alam, Jason S. McLellan, Georgia D. Tomaras, M. Anthony Moody, Daniel M. Kozink, Kwan-Ki Hwang, Xi Chen, Chun-Yen Tsao, Pinghuang Liu, Xiaozhi Lu, Robert J. Parks, David C. Montefiori, Guido Ferrari, Justin Pollara, Mangala Rao, Kristina K. Peachman, Sampa Santra, Norman L. Letvin, Nicos Karasavvas, Zhi-Yong Yang, Kaifan Dai, Marie Pancera, Jason Gorman, Kevin Wiehe, Nathan I. Nicely, Supachai Rerks-Ngarm, Sorachai Nitayaphan, Jaranit Kaewkungwal, Punnee Pitisuttithum, James Tartaglia, Faruk Sinangil, Jerome H. Kim, Nelson L. Michael, Thomas B. Kepler, Peter D. Kwong, John R. Mascola, Gary J. Nabel, Abraham Pinter, Susan Zolla-Pazner, Barton F. Haynes. (2013) Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. Immunity 38:1, 176-186
93
Galit Alter, Margaret E. Ackerman. (2013) What mAbs Tell Us about Shapes: Multiple Roads Lead to Rome. Immunity 38:1, 8-9
94
Elizabeth K Nelson, Britt Piehler, Adam Rauch, Sarah Ramsay, Drienna Holman, Smita Asare, Adam Asare, Mark Igra. (2013) Ancillary study management systems: a review of needs. BMC Medical Informatics and Decision Making 13:1, 5
95
Anuska Llano, Jorge Carrillo, Beatriz Mothe, Lidia Ruiz, Silvia Marfil, Elisabet García, Eloísa Yuste, Víctor Sánchez, Bonaventura Clotet, Julià Blanco, Christian Brander. (2013) Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions. Journal of Translational Medicine 11:1, 48
96
Olga Pleguezuelos, Gregory A Stoloff, Wilson Caparros-Wanderley. (2013) Synthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation. Virology Journal 10:1, 107
97
M. Anthony Moody. Microbial Vaccine Development. In: Genomic and Personalized Medicine. Elsevier, 2013:1119-1128.
98
Hermancia S Eugene, Brooke R Pierce-Paul, Jodi K Cragio, Ted M Ross. (2013) Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge. Virology Journal 10:1, 102
99
Daniel J Stieh, Joshua L Phillips, Paul M Rogers, Deborah F King, Gianguido C Cianci, Simon A Jeffs, Sandrasegaram Gnanakaran, Robin J Shattock. (2013) Dynamic electrophoretic fingerprinting of the HIV-1 envelope glycoprotein. Retrovirology 10:1, 33
100
Josh Eckels, Cory Nathe, Elizabeth K Nelson, Sara G Shoemaker, Elizabeth Nostrand, Nicole L Yates, Vicki C Ashley, Linda J Harris, Mark Bollenbeck, Youyi Fong, Georgia D Tomaras, Britt Piehler. (2013) Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform. BMC Bioinformatics 14:1, 145
101
Adi Moseri, Subramanyam Tantry, Fa-Xiang Ding, Fred Naider, Jacob Anglister. (2012) Synergism Between a CD4-Mimic Peptide and Antibodies Elicited by a Constrained V3 Peptide. AIDS Research and Human Retroviruses121226065029006
102
Elena Martines, Isabel García, Marco Marradi, Daniel Padro, Soledad Penadés. (2012) Dissecting the Carbohydrate Specificity of the Anti-HIV-1 2G12 Antibody by Single-Molecule Force Spectroscopy. Langmuir 28:51, 17726-17732
103
D. E. Zak, E. Andersen-Nissen, E. R. Peterson, A. Sato, M. K. Hamilton, J. Borgerding, A. T. Krishnamurty, J. T. Chang, D. J. Adams, T. R. Hensley, A. I. Salter, C. A. Morgan, A. C. Duerr, S. C. De Rosa, A. Aderem, M. J. McElrath. (2012) PNAS Plus: Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity. Proceedings of the National Academy of Sciences 109:50, E3503-E3512
104
Lauren Levitz, Ousmane A. Koita, Kotou Sangare, Matthew T. Ardito, Christine M. Boyle, John Rozehnal, Karamoko Tounkara, Sounkalo M. Dao, Youssouf Koné, Zoumana Koty, Soren Buus, Leonard Moise, William D. Martin, Anne S. De Groot. (2012) Conservation of HIV-1 T cell epitopes across time and clades: Validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine. Vaccine 30:52, 7547-7560
105
Wilfried Posch, Sylvain Cardinaud, Chiraz Hamimi, Adam Fletcher, Annelies Mühlbacher, Klaus Loacker, Paul Eichberger, Manfred P. Dierich, Gianfranco Pancino, Cornelia Lass-Flörl, Arnaud Moris, Asier Saez-Cirion, Doris Wilflingseder. (2012) Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes. Journal of Allergy and Clinical Immunology 130:6, 1368-1374.e2
106
Sabra L. Klein. (2012) Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases. BioEssays 34:12, 1050-1059
107
Wei Lu, Song Chen, Chunhui Lai, Weizhong Guo, Linchun Fu, Jean-Marie Andrieu. (2012) Induction of CD8+ Regulatory T Cells Protects Macaques against SIV Challenge. Cell Reports 2:6, 1736-1746
108
Wiriya Rutvisuttinunt, Sunee Sirivichayakul, Sineenart Oota, Vatcharain Assawadarachai, Kultida Poltavee, Hathairat Savadsuk, Supanit Pattanachaiwit, Suwittra Chaemchuen, Miguel A. Arroyo, Robert M. Paris, Nelson L. Michael, Jerome H. Kim, Kiat Ruxrungtham, Mark de Souza, Praphan Phanuphak, Sodsai Tovanabutra. (2012) Two Unique Recombinant Forms Identified in Incident HIV Type 1 Infections in Thai Blood Donors. AIDS Research and Human Retroviruses 28:12, 1703-1711
109
Mitzi M. Donaldson, Shing-Fen Kao, Leila Eslamizar, Connie Gee, Gerrit Koopman, Michelle Lifton, Joern E. Schmitz, Andrew W. Sylwester, Aaron Wilson, Natalie Hawkins, Steve G. Self, Mario Roederer, Kathryn E. Foulds. (2012) Optimization and qualification of an 8-color intracellular cytokine staining assay for quantifying T cell responses in rhesus macaques for pre-clinical vaccine studies. Journal of Immunological Methods 386:1-2, 10-21
110
Y. Fong, J. Wakefield, S. De Rosa, N. Frahm. (2012) A Robust Bayesian Random Effects Model for Nonlinear Calibration Problems. Biometrics 68:4, 1103-1112
111
Dania O. Govea-Alonso, Erik E. Gómez-Cardona, Néstor Rubio-Infante, Ana Lilia García-Hernández, Javier T. Varona-Santos, Mariana Salgado-Bustamante, Schuyler S. Korban, Leticia Moreno-Fierros, Sergio Rosales-Mendoza. (2012) Production of an antigenic C4(V3)6 multiepitopic HIV protein in bacterial and plant systems. Plant Cell, Tissue and Organ Culture (PCTOC)
112
Alexander C. Tsai. (2012) A typology of structural approaches to HIV prevention: A commentary on Roberts and Matthews. Social Science & Medicine 75:9, 1562-1567
113
Catherine F. Houlihan, Natasha L. Larke, Deborah Watson-Jones, Karen K. Smith-McCune, Stephen Shiboski, Patti E. Gravitt, Jennifer S. Smith, Louise Kuhn, Chunhui Wang, Richard Hayes. (2012) Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS 26:17, 2211-2222
114
B. M. Meier, K. N. Brugh, Y. Halima. (2012) Conceptualizing a Human Right to Prevention in Global HIV/AIDS Policy. Public Health Ethics 5:3, 263-282
115
Lisa A. Eaton, Tania B. Huedo-Medina, Seth C. Kalichman, Jennifer A. Pellowski, Michael J. Sagherian, Michelle Warren, Ami R. Popat, Blair T. Johnson. (2012) Meta-Analysis of Single-Session Behavioral Interventions to Prevent Sexually Transmitted Infections: Implications for Bundling Prevention Packages. American Journal of Public Health 102:11, e34-e44
116
Nicos Karasavvas, Erik Billings, Mangala Rao, Constance Williams, Susan Zolla-Pazner, Robert T. Bailer, Richard A. Koup, Sirinan Madnote, Duangnapa Arworn, Xiaoying Shen, Georgia D. Tomaras, Jeffrey R. Currier, Mike Jiang, Craig Magaret, Charla Andrews, Raphael Gottardo, Peter Gilbert, Timothy J. Cardozo, Supachai Rerks-Ngarm, Sorachai Nitayaphan, Punnee Pitisuttithum, Jaranit Kaewkungwal, Robert Paris, Kelli Greene, Hongmei Gao, Sanjay Gurunathan, Jim Tartaglia, Faruk Sinangil, Bette T. Korber, David C. Montefiori, John R. Mascola, Merlin L. Robb, Barton F. Haynes, Viseth Ngauy, Nelson L. Michael, Jerome H. Kim, Mark S. de Souza, for the MOPH TAVEG Collab. (2012) The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. AIDS Research and Human Retroviruses 28:11, 1444-1457
117
Stefan D. Baral, Susanne Strömdahl, Chris Beyrer. (2012) The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs. Current Opinion in HIV and AIDS 7:6, 563-568
118
Vijaya Madhavi, Stephen J Kent, Ivan Stratov. (2012) HIV-specific antibody-dependent cellular cytotoxicity: a novel vaccine modality. Expert Review of Clinical Immunology 8:8, 767-774
119
Mattia Bonsignori, S. Munir Alam, Hua-Xin Liao, Laurent Verkoczy, Georgia D. Tomaras, Barton F. Haynes, M. Anthony Moody. (2012) HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends in Microbiology 20:11, 532-539
120
David V. Glidden. (2012) HIV: Design by trial. Nature 490:7420, 350-351
121
Ali Azizi, Kerrie Nichol Edamura, Glenda Leung, Lucy Gisonni-Lex, Laurent Mallet. (2012) Evaluating the Level of Expressed HIV Type 1 gp120 and gag Proteins in the vCP1521 Vector by Two Immunoplaque Methods. AIDS Research and Human Retroviruses121016061035002
122
D. N. Forthal, E. E. Gabriel, A. Wang, G. Landucci, T. B. Phan. (2012) Association of Fc receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood 120:14, 2836-2842
123
Ben Berkhout, Rogier W Sanders. (2012) Gene therapy as a vaccine for HIV-1. Expert Opinion on Biological Therapy 12:10, 1315-1321
124
G.M.N. Behrens. (2012) HIV 2012. Der Internist 53:10, 1187-1194
125
Peter A. Newman, Surachet Roungprakhon, Suchon Tepjan, Suzy Yim, Rachael Walisser. (2012) A social vaccine? Social and structural contexts of HIV vaccine acceptability among most-at-risk populations in Thailand. Global Public Health 7:9, 1009-1024
126
Marit Kramski, Gregor F. Lichtfuss, Marjon Navis, Gamze Isitman, Leia Wren, Grant Rawlin, Rob J. Center, Anthony Jaworowski, Stephen J. Kent, Damian F. J. Purcell. (2012) Anti-HIV-1 antibody-dependent cellular cytotoxicity mediated by hyperimmune bovine colostrum IgG. European Journal of Immunology 42:10, 2771-2781
127
Silawun Ampol, Kovit Pattanapanyasat, Ruengpung Sutthent, Parichart Permpikul, Wannee Kantakamalakul. (2012) Comprehensive Investigation of Common Antibody-Dependent Cell-Mediated Cytotoxicity Antibody Epitopes of HIV-1 CRF01_AE gp120. AIDS Research and Human Retroviruses 28:10, 1250-1258
128
Henry A.F. Stephens. (2012) Immunogenetic surveillance of HIV/AIDS. Infection, Genetics and Evolution 12:7, 1481-1491
129
David Hallengärd, Steven E. Applequist, Sanna Nyström, Anna-Karin Maltais, Mary Marovich, Bernard Moss, Patricia Earl, Kopek Nihlmark, Britta Wahren, Andreas Bråve. (2012) Immunization with Multiple Vaccine Modalities Induce Strong HIV-Specific Cellular and Humoral Immune Responses. Viral Immunology 25:5, 423-432
130
Thijs van Montfort, Rogier W Sanders. (2012) Optimizing cellular immunity against HIV-1 Gag and preventing suppression by HIV-1 gp120. Expert Review of Vaccines 11:10, 1175-1177
131
Jeremy Luban. (2012) Innate Immune Sensing of HIV-1 by Dendritic Cells. Cell Host & Microbe 12:4, 408-418
132
Joris Hemelaar. (2012) Implications of HIV diversity for the HIV-1 pandemic. Journal of Infection
133
M. Kramski, A. Schorcht, A.P.R. Johnston, G.F. Lichtfuss, S. Jegaskanda, R. De Rose, I. Stratov, A.D. Kelleher, M.A. French, R.J. Center, A. Jaworowski, S.J. Kent. (2012) Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity. Journal of Immunological Methods 384:1-2, 51-61
134
J. Pietzsch, H. Gruell, S. Bournazos, B. M. Donovan, F. Klein, R. Diskin, M. S. Seaman, P. J. Bjorkman, J. V. Ravetch, A. Ploss, M. C. Nussenzweig. (2012) A mouse model for HIV-1 entry. Proceedings of the National Academy of Sciences 109:39, 15859-15864
135
Derrick Louz, Hans E. Bergmans, Birgit P. Loos, Rob C. Hoeben. (2012) Animal models in virus research: their utility and limitations. Critical Reviews in Microbiology1-37
136
Morgane Rolland, Paul T. Edlefsen, Brendan B. Larsen, Sodsai Tovanabutra, Eric Sanders-Buell, Tomer Hertz, Allan C. deCamp, Chris Carrico, Sergey Menis, Craig A. Magaret, Hasan Ahmed, Michal Juraska, Lennie Chen, Philip Konopa, Snehal Nariya, Julia N. Stoddard, Kim Wong, Hong Zhao, Wenjie Deng, Brandon S. Maust, Meera Bose, Shana Howell, Adam Bates, Michelle Lazzaro, Annemarie O’Sullivan, Esther Lei, Andrea Bradfield, Grace Ibitamuno, Vatcharain Assawadarachai, Robert J. O’Connell, Mark S. deSouza, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Merlin L. Robb, Jason S. McLellan, Ivelin Georgiev, Peter D. Kwong, Jonathan M. Carlson, Nelson L. Michael, William R. Schief, Peter B. Gilbert, James I. Mullins, Jerome H. Kim. (2012) Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490:7420, 417-420
137
John T. Schiller, Douglas R. Lowy. (2012) Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nature Reviews Microbiology 10:10, 681-692
138
Jennifer Koen, Zaynab Essack, Catherine Slack, Graham Lindegger, Peter A. Newman. (2012) ‘It Looks Like You Just Want Them When Things Get Rough’: Civil Society Perspectives on Negative Trial Results and Stakeholder Engagement in HIV Prevention Trials. Developing World Bioethicsn/a-n/a
139
Zvavahera M Chirenje, Benoît R Mâsse, Lisa A Maslankowski, Gita Ramjee, Anne S Coletti, Tchangani N Tembo, Tsitsi M Magure, Lydia Soto-Torres, Cliff Kelly, Sharon Hillier, Abdool Karim. (2012) Utility of colposcopy in a phase 2 portion of a microbicide clinical trial of BufferGel and 0.5% PRO 2000 Gel. Journal of the International AIDS Society 15:2,
140
Havlir , Diane , Beyrer , Chris , . (2012) The Beginning of the End of AIDS?. New England Journal of Medicine 367:8, 685-687
Free Full Text141
Christian Melander, David M. Margolis. (2012) Medicinal chemistry: Forcing an enemy into the open. Nature Chemistry 4:9, 692-693
142
H. Yang, H. Wu, G. Hancock, G. Clutton, N. Sande, X. Xu, H. Yan, X. Huang, B. Angus, K. Kuldanek, S. Fidler, T. N. Denny, J. Birks, A. McMichael, L. Dorrell. (2012) Antiviral Inhibitory Capacity of CD8+ T cells Predicts the Rate of CD4+ T-Cell Decline in HIV-1 Infection. Journal of Infectious Diseases 206:4, 552-561
143
J. P. Williams, J. Frater. (2012) Current understanding in HIV immunopathology and treatment. QJM 105:8, 725-728
144
D. C. Montefiori, C. Karnasuta, Y. Huang, H. Ahmed, P. Gilbert, M. S. de Souza, R. McLinden, S. Tovanabutra, A. Laurence-Chenine, E. Sanders-Buell, M. A. Moody, M. Bonsignori, C. Ochsenbauer, J. Kappes, H. Tang, K. Greene, H. Gao, C. C. LaBranche, C. Andrews, V. R. Polonis, S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, S. G. Self, P. W. Berman, D. Francis, F. Sinangil, C. Lee, J. Tartaglia, M. L. Robb, B. F. Haynes, N. L. Michael, J. H. Kim. (2012) Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. Journal of Infectious Diseases 206:3, 431-441
145
Juan García-Arriaza, Pilar Arnáez, José Luis Jiménez, Carmen E. Gómez, María Ángeles Muñoz-Fernández, Mariano Esteban. (2012) Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors. Virus Research 167:2, 391-396
146
Myron S. Cohen, Kathryn E. Muessig, M. Kumi Smith, Kimberly A. Powers, Angela D.M. Kashuba. (2012) Antiviral agents and HIV prevention. AIDS 26:13, 1585-1598
147
Beryl A. Koblin, Kenneth H. Mayer, Elizabeth Noonan, Ching-Yun Wang, Michael Marmor, Jorge Sanchez, Stephen J. Brown, Michael N. Robertson, Susan P. Buchbinder. (2012) Sexual Risk Behaviors, Circumcision Status, and Preexisting Immunity to Adenovirus Type 5 Among Men Who Have Sex With Men Participating in a Randomized HIV-1 Vaccine Efficacy Trial. JAIDS Journal of Acquired Immune Deficiency Syndromes 60:4, 405-413
148
Jing Wen, Yi Yang, Guangyu Zhao, Shuang Tong, Hong Yu, Xia Jin, Lanying Du, Shibo Jiang, Zhihua Kou, Yusen Zhou. (2012) Salmonella typhi Ty21a bacterial ghost vector augments HIV-1 gp140 DNA vaccine-induced peripheral and mucosal antibody responses via TLR4 pathway. Vaccine 30:39, 5733-5739
149
M. Juliana McElrath, Bruce D. Walker. (2012) Is an HIV Vaccine Possible?. JAIDS Journal of Acquired Immune Deficiency Syndromes 60, S41-S43
150
Sandhya Vasan, Nelson L Michael. (2012) Improved outlook on HIV-1 prevention and vaccine development. Expert Opinion on Biological Therapy 12:8, 983-994
151
Morgan A. Reuter, Carolina Pombo, Michael R. Betts. (2012) Cytokine production and dysregulation in HIV pathogenesis: Lessons for development of therapeutics and vaccines. Cytokine & Growth Factor Reviews 23:4-5, 181-191
152
Arturo Reyes-Sandoval, Christine S Rollier, Anita Milicic, Karolis Bauza, Matthew G Cottingham, Choon-Kit Tang, Matthew D Dicks, Dong Wang, Rhea J Longley, David H Wyllie, Adrian VS Hill. (2012) Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity. Molecular Therapy 20:8, 1633-1647
153
Lisa M. McDaid, Graham J. Hart. (2012) Willingness to Participate in Future HIV Prevention Studies Among Gay and Bisexual Men in Scotland, UK: A Challenge for Intervention Trials. AIDS and Behavior 16:6, 1420-1429
154
Olivier D. Defawe, Youyi Fong, Evgenia Vasilyeva, Melissa Pickett, Donald K. Carter, Erin Gabriel, Supachai Rerks-Ngarm, Sorachai Nitayaphan, Nicole Frahm, M. Juliana McElrath, Stephen C. De Rosa. (2012) Optimization and qualification of a multiplex bead array to assess cytokine and chemokine production by vaccine-specific cells. Journal of Immunological Methods 382:1-2, 117-128
155
J. M. Kovacs, J. P. Nkolola, H. Peng, A. Cheung, J. Perry, C. A. Miller, M. S. Seaman, D. H. Barouch, B. Chen. (2012) HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proceedings of the National Academy of Sciences 109:30, 12111-12116
156
A. Duerr, Y. Huang, S. Buchbinder, R. W. Coombs, J. Sanchez, C. del Rio, M. Casapia, S. Santiago, P. Gilbert, L. Corey, M. N. Robertson, . (2012) Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study). Journal of Infectious Diseases 206:2, 258-266
157
(2012) Mining the mechanisms of an HIV vaccine. Nature Medicine 18:7, 1020-1021
158
Peter D Kwong, John R Mascola, Gary J Nabel. (2012) The changing face of HIV vaccine research. Journal of the International AIDS Society 15:2,
159
Sampa Santra, Mark Muldoon, Sydeaka Watson, Adam Buzby, Harikrishnan Balachandran, Kevin R. Carlson, Linh Mach, Wing-Pui Kong, Krisha McKee, Zhi-Yong Yang, Srinivas S. Rao, John R. Mascola, Gary J. Nabel, Bette T. Korber, Norman L. Letvin. (2012) Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology 428:2, 121-127
160
Lorne A Babiuk, Volker Gerdts. (2012) Future vaccines for a globalized world. Emerging Microbes & Infections 1:7, e4
161
José Esparza. (2012) Understanding the efficacy variables of an HIV vaccine trial. The Lancet Infectious Diseases 12:7, 499-500
162
Wendy A. Burgers, Amapola Manrique, David Masopust, Lyle R. McKinnon, Matthew R. Reynolds, Morgane Rolland, Catherine Blish, Gerald K. Chege, Rhonda Curran, William Fischer, Carolina Herrera, D. Noah Sather. (2012) Measurements of Immune Responses for Establishing Correlates of Vaccine Protection Against HIV. AIDS Research and Human Retroviruses 28:7, 641-648
163
Sorachai Nitayaphan, Viseth Ngauy, Robert O’Connell, Jean-Louis Excler. (2012) HIV epidemic in Asia: optimizing and expanding vaccine development. Expert Review of Vaccines 11:7, 805-819
164
Patrick S Sullivan, Alex Carballo-Diéguez, Thomas Coates, Steven M Goodreau, Ian McGowan, Eduard J Sanders, Adrian Smith, Prabuddhagopal Goswami, Jorge Sanchez. (2012) Successes and challenges of HIV prevention in men who have sex with men. The Lancet 380:9839, 388-399
165
PD Griffiths. (2012) HIV antibodies and athletes. Reviews in Medical Virology 22:4, 211-213
166
Merlin L Robb, Supachai Rerks-Ngarm, Sorachai Nitayaphan, Punnee Pitisuttithum, Jaranit Kaewkungwal, Prayura Kunasol, Chirasak Khamboonruang, Prasert Thongcharoen, Patricia Morgan, Michael Benenson, Robert M Paris, Joseph Chiu, Elizabeth Adams, Donald Francis, Sanjay Gurunathan, Jim Tartaglia, Peter Gilbert, Don Stablein, Nelson L Michael, Jerome H Kim. (2012) Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. The Lancet Infectious Diseases 12:7, 531-537
167
Jose M Martinez-Navio, Nuria Climent, Teresa Gallart, Carme Lluis, Rafael Franco. (2012) An old enzyme for current needs: adenosine deaminase and a dendritic cell vaccine for HIV. Immunology and Cell Biology 90:6, 594-600
168
Evan J Anderson, Ram Yogev. (2012) The glory of guidelines and the twilight of reality: controversies and challenges in the prevention and treatment of HIV in children. Expert Review of Anti-infective Therapy 10:7, 761-774
169
Nathaniel J. Schuldt, Andrea Amalfitano. (2012) Malaria vaccines: Focus on adenovirus based vectors. Vaccine 30:35, 5191-5198
170
J. Yin, M. T. Vahey, A. Dai, M. G. Lewis, T. Arango, J. Yalley-Ogunro, J. Greenhouse, K. Mendoza, A. Khan, N. Y. Sardesai, W. Weiss, J. Komisar, J. D. Boyer. (2012) Plasmodium inui Infection Reduces the Efficacy of a Simian Immunodeficiency Virus DNA Vaccine in a Rhesus Macaque Model Through Alteration of the Vaccine-Induced Immune Response. Journal of Infectious Diseases
171
Miroslaw K. Gorny, Ruimin Pan, Constance Williams, Xiao-Hong Wang, Barbara Volsky, Timothy O'Neal, Brett Spurrier, Jared M. Sampson, Liuzhe Li, Michael S. Seaman, Xiang-Peng Kong, Susan Zolla-Pazner. (2012) Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. Virology 427:2, 198-207
172
Kevin O. Saunders, Rebecca S. Rudicell, Gary J. Nabel. (2012) The design and evaluation of HIV-1 vaccines. AIDS 26:10, 1293-1302
173
Thumbi Ndung’u, Robin A. Weiss. (2012) On HIV diversity. AIDS 26:10, 1255-1260
174
Leonidas Stamatatos. (2012) HIV vaccine design: the neutralizing antibody conundrum. Current Opinion in Immunology 24:3, 316-323
175
Wayne C. Koff. (2012) HIV vaccine development: Challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Vaccine 30:29, 4310-4315
176
Matthew R. Reynolds, Andrea M. Weiler, Shari M. Piaskowski, Michael Piatak, Henry T. Robertson, David B. Allison, Andrew J. Bett, Danilo R. Casimiro, John W. Shiver, Nancy A. Wilson, Jeffrey D. Lifson, Wayne C. Koff, David I. Watkins. (2012) A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine 30:30, 4465-4475
177
Davide Corti, Antonio Lanzavecchia. (2012) Broadly Neutralizing Antiviral Antibodies. Annual Review of Immunology 31:1, 130118161850003
178
S. Elahi, T. Niki, M. Hirashima, H. Horton. (2012) Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection. Blood 119:18, 4192-4204
179
José Esparza. (2012) Solid vaccine protection against SIV in rhesus monkeys provides proof-of-concept for further evaluation of a novel HIV vaccine approach in humans. Expert Review of Vaccines 11:5, 539-542
180
Rui Gu, Cristy Stagnar, Lesya Zaichenko, Arlene I. Ramsingh. (2012) Induction of mucosal HIV-specific B and T cell responses after oral immunization with live coxsackievirus B4 recombinants. Vaccine 30:24, 3666-3674
181
J. Schlom. (2012) Therapeutic Cancer Vaccines: Current Status and Moving Forward. JNCI Journal of the National Cancer Institute 104:8, 599-613
182
Andrew J McMichael, Barton F Haynes. (2012) Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nature Immunology 13:5, 423-427
183
Baden , Lindsey R. , Dolin , Raphael , . (2012) The Road to an Effective HIV Vaccine. New England Journal of Medicine 366:14, 1343-1344
Full Text184
Haynes , Barton F. , Gilbert , Peter B. , McElrath , M. Juliana , Zolla-Pazner , Susan , Tomaras , Georgia D. , Alam , S. Munir , Evans , David T. , Montefiori , David C. , Karnasuta , Chitraporn , Sutthent , Ruengpueng , Liao , Hua-Xin , DeVico , Anthony L. , Lewis , George K. , Williams , Constance , Pinter , Abraham , Fong , Youyi , Janes , Holly , DeCamp , Allan , Huang , Yunda , Rao , Mangala , Billings , Erik , Karasavvas , Nicos , Robb , Merlin L. , Ngauy , Viseth , de Souza , Mark S. , Paris , Robert , Ferrari , Guido , Bailer , Robert T. , Soderberg , Kelly A. , Andrews , Charla , Berman , Phillip W. , Frahm , Nicole , De Rosa , Stephen C. , Alpert , Michael D. , Yates , Nicole L. , Shen , Xiaoying , Koup , Richard A. , Pitisuttithum , Punnee , Kaewkungwal , Jaranit , Nitayaphan , Sorachai , Rerks-Ngarm , Supachai , Michael , Nelson L. , Kim , Jerome H. , . (2012) Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. New England Journal of Medicine 366:14, 1275-1286
Free Full Text185
Jennifer Serwanga, Susan Mugaba, Edward Pimego, Bridget Nanteza, Fred Lyagoba, Susan Nakubulwa, Laura Heath, Rebecca N. Nsubuga, Nicaise Ndembi, Frances Gotch, Pontiano Kaleebu. (2012) Profile of T Cell Recognition of HIV Type 1 Consensus Group M Gag and Nef Peptides in a Clade A1- and D-Infected Ugandan Population. AIDS Research and Human Retroviruses 28:4, 384-392
186
Antu K. Dey, Brian Burke, Yide Sun, Karin Hartog, Jonathan L. Heeney, David Montefiori, Indresh K. Srivastava, Susan W. Barnett. (2012) Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. Vaccine 30:17, 2749-2759
187
John P Moore. (2012) HIV-1 Env antibodies: are we in a bind or going blind?. Nature Medicine 18:3, 346-347
188
F. Di Nunzio, T. Félix, N.J. Arhel, S. Nisole, P. Charneau, A-S. Beignon. (2012) HIV-derived vectors for therapy and vaccination against HIV. Vaccine 30:15, 2499-2509
189
Lyle R. McKinnon, Rupert Kaul. (2012) Quality and quantity. Current Opinion in HIV and AIDS 7:2, 195-202
190
Ramesh S. Paranjape, Madhuri R. Thakar, Manisha V. Ghate, Sheela V. Godbole. (2012) Current Status of Research on HIV Epidemic, Pathogenesis, Management and Prevention in India. Proceedings of the National Academy of Sciences, India Section B: Biological Sciences 82:1, 167-180
191
Sergio Rosales-Mendoza, Néstor Rubio-Infante, Dania O. Govea-Alonso, Leticia Moreno-Fierros. (2012) Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV). Plant Cell Reports 31:3, 495-511
192
Tobias Boettler, Edecio Cunha-Neto, Jorge Kalil, Matthias von Herrath. (2012) Can an immune-regulatory vaccine prevent HIV infection?. Expert Review of Anti-infective Therapy 10:3, 299-305
193
Ennio De Gregorio, Rino Rappuoli. (2012) Vaccines for the future: learning from human immunology. Microbial Biotechnology 5:2, 149-155
194
Kaushik Bharati, Sudhanshu Vrati. (2012) Viral Vaccines in India: An Overview. Proceedings of the National Academy of Sciences, India Section B: Biological Sciences 82:1, 181-198
195
Larisa I. Karpenko, Alexey V. Danilenko, Sergei I. Bazhan, Elena D. Danilenko, Galina M. Sysoeva, Olga N. Kaplina, Olga Y. Volkova, Svetlana F. Oreshkova, Alexander A. Ilyichev. (2012) Attenuated Salmonella enteritidis E23 as a vehicle for the rectal delivery of DNA vaccine coding for HIV-1 polyepitope CTL immunogen. Microbial Biotechnology 5:2, 241-250
196
Joris Hemelaar. (2012) The origin and diversity of the HIV-1 pandemic. Trends in Molecular Medicine 18:3, 182-192
197
James G Kublin, Cecilia A Morgan, Tracey A Day, Peter B Gilbert, Steve G Self, M Juliana McElrath, Lawrence Corey. (2012) HIV Vaccine Trials Network: activities and achievements of the first decade and beyond. Clinical Investigation 2:3, 245-254
198
Erik De Clercq. (2012) Pre-exposure chemoprophylaxis of HIV infection: Quo vadis?. Biochemical Pharmacology 83:5, 567-573
199
Ann J. Hessell, Nancy L. Haigwood. (2012) Neutralizing Antibodies and Control of HIV: Moves and Countermoves. Current HIV/AIDS Reports 9:1, 64-72
200
D. Z. Soghoian, H. Jessen, M. Flanders, K. Sierra-Davidson, S. Cutler, T. Pertel, S. Ranasinghe, M. Lindqvist, I. Davis, K. Lane, J. Rychert, E. S. Rosenberg, A. Piechocka-Trocha, A. L. Brass, J. M. Brenchley, B. D. Walker, H. Streeck. (2012) HIV-Specific Cytolytic CD4 T Cell Responses During Acute HIV Infection Predict Disease Outcome. Science Translational Medicine 4:123, 123ra25-123ra25
201
Margaret E. Ackerman, Anne-Sophie Dugast, Galit Alter. (2012) Emerging Concepts on the Role of Innate Immunity in the Prevention and Control of HIV Infection. Annual Review of Medicine 63:1, 113-130
202
Louis J. Picker, Scott G. Hansen, Jeffrey D. Lifson. (2012) New Paradigms for HIV/AIDS Vaccine Development. Annual Review of Medicine 63:1, 95-111
203
Niall McMullan. Vaccine Design and Vaccination. In: Molecular and Cellular Therapeutics. John Wiley & Sons, Ltd, 2012:286-303.
204
David S. Campo, Zoya Dimitrova, Jonny Yokosawa, Duc Hoang, Nestor O. Perez, Sumathi Ramachandran, Yury Khudyakov. (2012) Hepatitis C Virus Antigenic Convergence. Scientific Reports 2,
205
Eduardo Castro-Nallar, Marcos Pérez-Losada, Gregory F. Burton, Keith A. Crandall. (2012) The evolution of HIV: Inferences using phylogenetics. Molecular Phylogenetics and Evolution 62:2, 777-792
206
Josephine H. Cox, Maria G. Ferrari, Patricia Earl, James R. Lane, Linda L. Jagodzinski, Victoria R. Polonis, Ellen G. Kuta, Jean D. Boyer, Silvia Ratto-Kim, Leigh-Anne Eller, Doan-Trang Pham, Lydia Hart, David Montefiori, Guido Ferrari, Stephanie Parrish, David B. Weiner, Bernard Moss, Jerome H. Kim, Deborah Birx, Thomas C. VanCott. (2012) Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge. Vaccine 30:10, 1830-1840
207
Basile Siewe, Alan Landay. (2012) Key Concepts in the Early Immunology of HIV-1 Infection. Current Infectious Disease Reports 14:1, 102-109
208
Andrea Gorlani, Joachim Brouwers, Christopher McConville, Pieter van der Bijl, Karl Malcolm, Patrick Augustijns, Anna Forsman Quigley, Robin Weiss, Hans De Haard, Theo Verrips. (2012) Llama Antibody Fragments Have Good Potential for Application as HIV Type 1 Topical Microbicides. AIDS Research and Human Retroviruses 28:2, 198-205
209
Nawal Ben Haij, Olfa Mzoughi, Rémi Planès, Elmostafa Bahraoui. (2012) Cationic nanoglycolipidic particles as vector and adjuvant for the study of the immunogenicity of SIV Nef protein. International Journal of Pharmaceutics 423:1, 116-123
210
Dan H. Barouch, Jinyan Liu, Hualin Li, Lori F. Maxfield, Peter Abbink, Diana M. Lynch, M. Justin Iampietro, Adam SanMiguel, Michael S. Seaman, Guido Ferrari, Donald N. Forthal, Ilnour Ourmanov, Vanessa M. Hirsch, Angela Carville, Keith G. Mansfield, Donald Stablein, Maria G. Pau, Hanneke Schuitemaker, Jerald C. Sadoff, Erik A. Billings, Mangala Rao, Merlin L. Robb, Jerome H. Kim, Mary A. Marovich, Jaap Goudsmit, Nelson L. Michael. (2012) Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482:7383, 89-93
211
Nelson L. Michael. (2012) Rare serotype adenoviral vectors for HIV vaccine development. Journal of Clinical Investigation 122:1, 25-27
212
Jeremy Luban. (2012) TRIM5 and the Regulation of HIV-1 Infectivity. Molecular Biology International 2012, 1-6
213
Mark Page, Richard Stebbings, Neil Berry, Robin Hull, Deborah Ferguson, Leanne Davis, Laura Duffy, William Elsley, Joanna Hall, Claire Ham, Mark Hassall, Bo Li, Edward T Mee, Ruby Quartey-Papafio, Nicola J Rose, Nathalie Mathy, Gerald Voss, E Stott, Neil Almond. (2012) Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model. Retrovirology 9:1, 56
214
Andrew J. Mouland, Miroslav P. Milev. Role of Dynein in Viral Pathogenesis. In: Dyneins. Elsevier, 2012:560-583.
215
Chevonne Reynolds, Charles B. de Koning, Stephen C. Pelly, Willem A. L. van Otterlo, Moira L. Bode. (2012) In search of a treatment for HIV – current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs). Chemical Society Reviews 41:13, 4657
216
Ingvild Sandøy, Astrid Blystad, Elizabeth H Shayo, Emmanuel Makundi, Charles Michelo, Joseph Zulu, Jens Byskov. (2012) Condom availability in high risk places and condom use: a study at district level in Kenya, Tanzania and Zambia. BMC Public Health 12:1, 1030
217
Jacques Fellay, Amalio Telenti. Genetic Associations with Resistance to HIV-1 Infection, Viral Control and Protection Against Disease. In: Models of Protection Against HIV/SIV. Elsevier, 2012:319-334.
218
Nicolas Ruffin, Marie Borggren, Zelda Euler, Fabio Fiorino, Katrijn Grupping, David Hallengärd, Aneele Javed, Kevin Mendonca, Charlotte Pollard, David Reinhart, Elisa Saba, Enas Sheik-Khalil, Annette Sköld, Serena Ziglio, Gabriella Scarlatti, Frances Gotch, Britta Wahren, Robin J Shattock. (2012) Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011. Journal of Translational Medicine 10:1, 144
219
Elias K. Haddad, Giuseppe Pantaleo. (2012) Systems biology in the development of HIV vaccines. Current Opinion in HIV and AIDS 7:1, 44-49
220
Carlos Del Rio. Prevention of Human Immunodeficiency Virus Infection. In: Goldman's Cecil Medicine. Elsevier, 2012:2182-2185.
221
Salim S. Abdool Karim. HIV prevention. In: Sande's HIV/AIDS Medicine. Elsevier, 2012:113-121.
222
Lai-Xi Wang. Carbohydrate-Based Vaccines against HIV/AIDS. American Chemical Society, 2012:157-186.
223
Robert Paris, Sasitorn Bejrachandra, Prasert Thongcharoen, Sorachai Nitayaphan, Punnee Pitisuttithum, Anna Sambor, Sanjay Gurunathan, Donald Francis, Silvia Ratto-Kim, Chitraporn Karnasuta, Mark S. de Souza, Victoria R. Polonis, Arthur E. Brown, Jerome H. Kim, Henry A. Stephens. (2012) HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX® B/E. Vaccine 30:5, 832-836
224
Maximillian Rosario, Nicola Borthwick, Guillaume B. Stewart-Jones, Alice Mbewe-Mvula, Anne Bridgeman, Stefano Colloca, David Montefiori, Andrew J. McMichael, Alfredo Nicosia, Esther D. Quakkelaar, Jan W. Drijfhout, Cornelis J.M. Melief, Tomáš Hanke. (2012) Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. AIDS 26:3, 275-284
225
Guido Vanham, Ellen Van Gulck. (2012) Can immunotherapy be useful as a “functional cure” for infection with Human Immunodeficiency Virus-1?. Retrovirology 9:1, 72
226
Sarah C. Gilbert. (2012) T-cell-inducing vaccines - what’s the future. Immunology 135:1, 19-26
227
Henry Masur, Letha Healey, Colleen Hadigan. Treatment of Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome. In: Goldman's Cecil Medicine. Elsevier, 2012:2185-2196.
228
Daniel E. Zak, Alan Aderem. (2012) Overcoming limitations in the systems vaccinology approach. Current Opinion in HIV and AIDS 7:1, 58-63
229
Charlene N Muzyka, Laura H Thompson, Andrea E Bombak, S Driedger, Robert Lorway. (2012) A Kenyan newspaper analysis of the limitations of voluntary medical male circumcision and the importance of sustained condom use. BMC Public Health 12:1, 465
230
Erica Andersen-Nissen, Antje Heit, M. Juliana McElrath. (2012) Profiling immunity to HIV vaccines with systems biology. Current Opinion in HIV and AIDS 7:1, 32-37
231
Austin Pantel, Cheolho Cheong, Durga Dandamudi, Elina Shrestha, Saurabh Mehandru, Luke Brane, Darren Ruane, Angela Teixeira, Leonia Bozzacco, Ralph M. Steinman, M. Paula Longhi. (2012) A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo. European Journal of Immunology 42:1, 101-109
232
Jerome H. Kim, Nelson L. Michael. The design of a global HIV vaccine. In: Sande's HIV/AIDS Medicine. Elsevier, 2012:97-112.
233
Justin J. O’Hagan, Miguel A. Hernán, Rochelle P. Walensky, Marc Lipsitch. (2012) Apparent declining efficacy in randomized trials. AIDS 26:2, 123-126
234
Koen K.A. Van Rompay. (2012) The Use of Nonhuman Primate Models of HIV Infection for the Evaluation of Antiviral Strategies. AIDS Research and Human Retroviruses 28:1, 16-35
235
Gamze Isitman, Ivan Stratov, Stephen J. Kent. (2012) Antibody-Dependent Cellular Cytotoxicity and NK Cell-Driven Immune Escape in HIV Infection: Implications for HIV Vaccine Development. Advances in Virology 2012, 1-8
236
Rafick Sekaly, Bali Pulendran. (2012) Systems biology in understanding HIV pathogenesis and guiding vaccine development. Current Opinion in HIV and AIDS 7:1, 1-3
237
Jun Yong Choi, June Myung Kim. (2012) Updates on the prevention and treatment of AIDS. Journal of the Korean Medical Association 55:2, 146
238
Marc P. Girard, Stanley A. Plotkin. (2012) HIV vaccine development at the turn of the 21st century. Current Opinion in HIV and AIDS 7:1, 4-9
239
Clive M. Gray, Pamela Gumbi, Lycias Zembe, Mopo Radebe, Bruce Walker. The immune response to HIV. In: Sande's HIV/AIDS Medicine. Elsevier, 2012:45-57.
240
Peter A Newman. (2012) Integrating social and biomedical science in HIV vaccine research: obstacles, opportunities and ways forward. Expert Review of Vaccines 11:1, 1-3
241
Robert A. Rasmussen, Nagadenahalli B. Siddappa, Samir K. Lakhashe, Jennifer Watkins, François Villinger, Chris Ibegbu, Ruth H. Florese, Marjorie Robert-Guroff, David C. Montefiori, Donald N. Forthal, David O’Connor, Ruth M. Ruprecht. (2012) High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure. AIDS 26:2, 149-155
242
Helder I. Nakaya, Bali Pulendran. (2012) Systems vaccinology. Current Opinion in HIV and AIDS 7:1, 24-31
243
Girish N. Vyas, Cheryl A. Stoddart, M. Scott Killian, Todd V. Brennan, Tiffany Goldberg, Alyssa Ziman, Yvonne Bryson. (2012) Derivation of non-infectious envelope proteins from virions isolated from plasma negative for HIV antibodies. Biologicals 40:1, 15-20
244
F. K. Sawe. (2012) Access to Universal HIV Care and Prevention Services: Light at the End of a Long Tunnel?. Clinical Infectious Diseases 54:1, 119-120
245
Marc H. V. Regenmortel. (2012) Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. Archives of Virology 157:1, 1-20
246
Per Klasse, John P Moore. (2012) Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines. Retrovirology 9:1, 80
247
G. Bocharov, V. Chereshnev, I. Gainova, S. Bazhan, B. Bachmetyev, J. Argilaguet, J. Martinez, A. Meyerhans. (2012) Human Immunodeficiency Virus Infection : from Biological Observations to Mechanistic Mathematical Modelling. Mathematical Modelling of Natural Phenomena 7:5, 78-104
248
Christopher A. Todd, Kelli M. Greene, Xuesong Yu, Daniel A. Ozaki, Hongmei Gao, Yunda Huang, Maggie Wang, Gary Li, Ronald Brown, Blake Wood, M. Patricia D'Souza, Peter Gilbert, David C. Montefiori, Marcella Sarzotti-Kelsoe. (2012) Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. Journal of Immunological Methods 375:1-2, 57-67
249
Raghavan Sampathkumar, Elnaz Shadabi, Ma Luo. (2012) Interplay between HIV-1 and Host Genetic Variation: A Snapshot into Its Impact on AIDS and Therapy Response. Advances in Virology 2012, 1-16
250
J. M. Marrazzo, W. Cates. (2011) Interventions to Prevent Sexually Transmitted Infections, Including HIV Infection. Clinical Infectious Diseases 53:suppl 3, S64-S78
251
Susan Moir, Angela Malaspina, Anthony S Fauci. (2011) Prospects for an HIV vaccine: leading B cells down the right path. Nature Structural & Molecular Biology 18:12, 1317-1321
252
Lynne M. Mofenson. (2011) Prevention of Mother-to-Child HIV-1 Transmission—Why We Still Need a Preventive HIV Immunization Strategy. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:4, 359-362
253
Ronald O. Valdiserri. (2011) Commentary: Thirty Years of AIDS in America: A Story of Infinite Hope. AIDS Education and Prevention 23:6, 479-494
254
M. Scott Killian, Jay A. Levy. (2011) HIV/AIDS: 30 Years of progress and future challenges. European Journal of Immunology 41:12, 3401-3411
255
Tomáš Hanke, Andrew J. McMichael. (2011) HIV-1: From escapism to conservatism. European Journal of Immunology 41:12, 3390-3393
256
Fernando Maltêz, Manuela Doroana, Teresa Branco, Cristina Valente. (2011) Recent advances in antiretroviral treatment and prevention in HIV-infected patients. Current Opinion in HIV and AIDS 6, S21-S30
257
Francisco Antunes. (2011) Antiretroviral therapy for naïve and for treatment-experienced HIV patients, and prevention of HIV transmission. Current Opinion in HIV and AIDS 6, S1-S2
258
Thomas C. Quinn. (2011) The 30-Year War on AIDS: Have We Reached the Tipping Point?. Sexually Transmitted Diseases 38:12, 1089-1093
259
Cecilia T Costiniuk, Jonathan B Angel. (2011) ALVAC-HIV as a prophylactic and therapeutic vaccine: highlights from over a decade of clinical trials. Future Virology 6:12, 1481-1492
260
G.J.V. Nossal. (2011) Vaccines of the future. Vaccine 29, D111-D115
261
Salim S Abdool Karim, Quarraisha Abdool Karim. (2011) Antiretroviral prophylaxis: a defining moment in HIV control. The Lancet 378:9809, e23-e25
262
Myron M. Levine. (2011) “IDEAL” vaccines for resource poor settings. Vaccine 29, D116-D125
263
Izabela Bialuk, Stephen Whitney, Vibeke Andresen, Ruth H. Florese, Janos Nacsa, Valentina Cecchinato, Valerio W. Valeri, Jean-Michel Heraud, Shari Gordon, Robyn Washington Parks, David C. Montefiori, David Venzon, Thorsten Demberg, Marjorie Robert- Guroff, Gary Landucci, Donald N. Forthal, Genoveffa Franchini. (2011) Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques. Vaccine 30:1, 78-94
264
Richard Hopkins, Anne Bridgeman, Charles Bourne, Alice Mbewe-Mvula, Jerald C. Sadoff, Gerald W. Both, Joan Joseph, John Fulkerson, Tomáš Hanke. (2011) Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors. European Journal of Immunology 41:12, 3542-3552
265
L. R. Baden, W. A. Blattner, C. Morgan, Y. Huang, O. D. Defawe, M. E. Sobieszczyk, N. Kochar, G. D. Tomaras, M. J. McElrath, N. Russell, K. Brandariz, M. Cardinali, B. S. Graham, D. H. Barouch, R. Dolin, . (2011) Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects. Journal of Infectious Diseases 204:10, 1541-1549
266
E. H. J. G. Aarntzen, M. Srinivas, J. H. W. De Wilt, J. F. M. Jacobs, W. J. Lesterhuis, A. D. Windhorst, E. G. Troost, J. J. Bonenkamp, M. M. van Rossum, W. A. M. Blokx, R. D. Mus, O. C. Boerman, C. J. A. Punt, C. G. Figdor, W. J. G. Oyen, I. J. M. de Vries. (2011) Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging. Proceedings of the National Academy of Sciences 108:45, 18396-18399
267
A. Burgener, S. Rahman, R. Ahmad, J. Lajoie, S. Ramdahin, C. Mesa, S. Brunet, C. Wachihi, J. Kimani, K. Fowke, S. Carr, F. Plummer, T. B. Ball. (2011) Comprehensive Proteomic Study Identifies Serpin and Cystatin Antiproteases as Novel Correlates of HIV-1 Resistance in the Cervicovaginal Mucosa of Female Sex Workers. Journal of Proteome Research 10:11, 5139-5149
268
Joseph C. Forbi, Peter E. Entonu, Lulu O. Mwangi, Simon M. Agwale. (2011) Estimates of human immunodeficiency virus incidence among female sex workers in north central Nigeria: implications for HIV clinical trials. Transactions of the Royal Society of Tropical Medicine and Hygiene 105:11, 655-660
269
John Goulding, Vikas Tahiliani, Shahram Salek-Ardakani. (2011) OX40:OX40L axis: emerging targets for improving poxvirus-based CD8+ T-cell vaccines against respiratory viruses. Immunological Reviews 244:1, 149-168
270
Diego A. Vargas-Inchaustegui, Thorsten Demberg, Marjorie Robert-Guroff. (2011) A CD8α− subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities. Immunology 134:3, 326-340
271
Dobromir T. Dimitrov, Marie-Claude Boily, Rebecca F. Baggaley, Benoit Masse. (2011) Modeling the gender-specific impact of vaginal microbicides on HIV transmission. Journal of Theoretical Biology 288, 9-20
272
Ji Wang, Liling Xu, Pei Tong, Ying-Hua Chen. (2011) Mucosal antibodies induced by tandem repeat of 2F5 epitope block transcytosis of HIV-1. Vaccine 29:47, 8542-8548
273
Beryl A. Koblin, Gordon Mansergh, Victoria Frye, Hong Van. Tieu, Donald R. Hoover, Sebastian Bonner, Stephen A. Flores, Sharon M. Hudson, Grant N. Colfax. (2011) Condom-Use Decision Making in the Context of Hypothetical Pre-Exposure Prophylaxis Efficacy Among Substance-Using Men Who Have Sex With Men. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:3, 319-327
274
Chintan Chhatbar, Ritu Mishra, Ashish Kumar, Sunit Kumar Singh. (2011) HIV vaccine: hopes and hurdles. Drug Discovery Today 16:21-22, 948-956
275
John Stover. (2011) 30 years after HIV identification: where to from here?. Expert Review of Anti-infective Therapy 9:11, 947-949
276
Nunzia Scotti, Luigi Buonaguro, Maria Lina Tornesello, Teodoro Cardi, Franco Maria Buonaguro. Plant-derived anti-HIV-1 proteins. In: Plant-derived Vaccines: Technologies & Applications. Future Medicine Ltd, 2011:82-93.
277
G. J. V. Nossal. (2011) Vaccines and future global health needs. Philosophical Transactions of the Royal Society B: Biological Sciences 366:1579, 2833-2840
278
G. J. Nabel, P. D. Kwong, J. R. Mascola. (2011) Progress in the rational design of an AIDS vaccine. Philosophical Transactions of the Royal Society B: Biological Sciences 366:1579, 2759-2765
279
B. Greenwood, D. Salisbury, A. V. S. Hill. (2011) Vaccines and global health. Philosophical Transactions of the Royal Society B: Biological Sciences 366:1579, 2733-2742
280
Bruce D Walker, Rafi Ahmed, Stanley Plotkin. (2011) Moving ahead an HIV vaccine: Use both arms to beat HIV. Nature Medicine 17:10, 1194-1195
281
Thomas J Hope. (2011) Moving ahead an HIV vaccine: To neutralize or not, a key HIV vaccine question. Nature Medicine 17:10, 1195-1197
282
Susanne E. Johansson, Erik Rollman, Amy W. Chung, Rob J. Center, Bo Hejdeman, Ivan Stratov, Jorma Hinkula, Britta Wahren, Klas Kärre, Stephen J. Kent, Louise Berg. (2011) NK Cell Function and Antibodies Mediating ADCC in HIV-1-Infected Viremic and Controller Patients. Viral Immunology 24:5, 359-368
283
Thomas Mourez, Mariana Mesel-Lemoine, Chantal Combredet, Valérie Najburg, Nadège Cayet, Frédéric Tangy. (2011) A chimeric measles virus with a lentiviral envelope replicates exclusively in CD4+/CCR5+ cells. Virology 419:2, 117-125
284
Amy W Chung, Marjon Navis, Gamze Isitman, Leia Wren, Julie Silvers, Janaki Amin, Stephen J Kent, Ivan Stratov. (2011) Activation of NK Cells by ADCC Antibodies and HIV Disease Progression. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:2, 127-131
285
Erin L Lousberg, Kerrilyn R Diener, Michael P Brown, John D Hayball. (2011) Innate immune recognition of poxviral vaccine vectors. Expert Review of Vaccines 10:10, 1435-1449
286
Paul Swain. (2011) Future Innovative Therapies to Treat Upper Gastrointestinal Bleeding. Gastrointestinal Endoscopy Clinics of North America 21:4, 739-747
287
Muhammad Bakari, Said Aboud, Charlotta Nilsson, Joel Francis, Deus Buma, Candida Moshiro, Eric A. Aris, Eligius F. Lyamuya, Mohamed Janabi, Karina Godoy-Ramirez, Agricola Joachim, Victoria R. Polonis, Andreas Bråve, Patricia Earl, Merlin Robb, Mary Marovich, Britta Wahren, Kisali Pallangyo, Gunnel Biberfeld, Fred Mhalu, Eric Sandström. (2011) Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 29:46, 8417-8428
288
J.R. Abbott, M.P. Sanou, J.K. Coleman, J.K. Yamamoto. (2011) Evolutionarily conserved T-cell epitopes on FIV for designing an HIV/AIDS vaccine. Veterinary Immunology and Immunopathology 143:3-4, 246-254
289
Kennedy N Otwombe, Kathleen J Sikkema, Janan Dietrich, Guy de Bruyn, Martin van der Watt, Glenda E Gray. (2011) Willingness to Participate in Biomedical HIV Prevention Studies After the HVTN 503/Phambili Trial: A Survey Conducted Among Adolescents in Soweto, South Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:2, 211-218
290
Samir K Lakhashe, Guido Silvestri, Ruth M Ruprecht. (2011) No acquisition: A new ambition for HIV vaccine development?. Current Opinion in Virology 1:4, 246-253
291
Amanda L Harrison, Stephen Henry, Radhia Mahfoud, Adam Manis, Aurelie Albertini, Yves Gaudin, Clifford A Lingwood, Donald R Branch. (2011) A novel VSV/HIV pseudotype approach for the study of HIV microbicides without requirement for level 3 biocontainment. Future Virology 6:10, 1241-1259
292
Hildegund Ertl, Bali Pulendran. (2011) Editorial overview. Current Opinion in Virology 1:4, 223-225
293
Felipe García, Juan Carlos López Bernaldo de Quirós, Carmen E. Gómez, Beatriz Perdiguero, Jose L. Nájera, Victoria Jiménez, Juan García-Arriaza, Alberto C. Guardo, Iñaki Pérez, Vicens Díaz-Brito, Matilde Sánchez Conde, Nuria González, Amparo Alvarez, José Alcamí, José Luis Jiménez, Judit Pich, Joan Albert Arnaiz, María J. Maleno, Agathe León, María Angeles Muñoz-Fernández, Peter Liljeström, Jonathan Weber, Giuseppe Pantaleo, José M. Gatell, Montserrat Plana, Mariano Esteban. (2011) Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine 29:46, 8309-8316
294
Natalie A Hutnick, Devin JF Myles, Chaoran Billie Bian, Karuppiah Muthumani, David B Weiner. (2011) Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Current Opinion in Virology 1:4, 233-240
295
David L. Blazes, Kevin L. Russell. (2011) Medicine in war and peace: Joining forces. Nature 477:7365, 395-396
296
Ewen Callaway. (2011) Clues emerge to explain first successful HIV vaccine trial. Nature
297
Johnston , Margaret I. , Fauci , Anthony S. , . (2011) HIV Vaccine Development — Improving on Natural Immunity. New England Journal of Medicine 365:10, 873-875
Free Full Text298
Peter A. Newman, Carmen Logie, LLana James, Tamicka Charles, John Maxwell, Khaled Salam, Michael Woodford. (2011) “Speaking the Dialect”: Understanding Public Discourse in the Aftermath of an HIV Vaccine Trial Shutdown. American Journal of Public Health 101:9, 1749-1758
299
Leolin Katsidzira, James G. Hakim. (2011) HIV prevention in southern Africa: why we must reassess our strategies?. Tropical Medicine & International Health 16:9, 1120-1130
300
Paolo Palma, Maria Luisa Romiti, Giuseppina Li Pira, Carla Montesano, Nadia Mora, Angela Aquilani, Veronica Santilli, Hyppolite K. Tchidjou, Federico Ivaldi, Luigi Giovannelli, Giuseppe Pontrelli, Giada Borra, Pontus Blomberg, Lindvi Gudmundsdotter, Andreas Bråve, Marco Montano, Stefania Bernardi, Fabrizio Manca, Britta Wahren, Paolo Rossi. (2011) The PEDVAC trial: Preliminary data from the first therapeutic DNA vaccination in HIV-infected children. Vaccine 29:39, 6810-6816
301
Yoshiaki Nishimura, Malcolm A Martin. (2011) The acute HIV infection: implications for intervention, prevention and development of an effective AIDS vaccine. Current Opinion in Virology 1:3, 204-210
302
Lucia Lopalco, Morgane Bomsel. (2011) Protecting the initial site of viral entry: an alternative HIV vaccine target. Expert Review of Vaccines 10:9, 1253-1256
303
Rada Ellegård, Esaki M. Shankar, Marie Larsson. (2011) Targeting HIV-1 innate immune responses therapeutically. Current Opinion in HIV and AIDS 6:5, 435-443
304
Yves Lévy. (2011) Perpetuation of vaccine memory T cell responses against SIV/HIV. EMBO Molecular Medicine 3:9, 507-509
305
Cecilia Cheng-Mayer, Yaoxing Huang, Agegnehu Gettie, Lily Tsai, Wuze Ren, Madina Shakirzyanova, Silvana T. Sina, Nataliya Trunova, James Blanchard, Lisa M. Miller Jenkins, Yungtai Lo, Marco L. Schito, Ettore Appella. (2011) Delay of simian human immunodeficiency virus infection and control of viral replication in vaccinated macaques challenged in the presence of a topical microbicide. AIDS 25:15, 1833-1841
306
Lawrence R. Stanberry, Richard Strugnell. (2011) Vaccines of the future. Perspectives in Vaccinology 1:1, 151-199
307
Elisa F. Long, Douglas K. Owens. (2011) The cost-effectiveness of a modestly effective HIV vaccine in the United States. Vaccine 29:36, 6113-6124
308
Marc P. Girard, Saladin Osmanov, Olga M. Assossou, Marie-Paule Kieny. (2011) Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review. Vaccine 29:37, 6191-6218
309
Haitham Ghunaim, Ashok Kumar, Jose Torres, Francisco Diaz-Mitoma, Ali Azizi. (2011) An immunological comparison between lipidated and non-lipidated multivalent HIV-1 peptides representing Gp120 and Gag hypervariable regions. Vaccine 29:35, 5950-5958
310
Catherine A. Hankins, John W. Glasser, Robert T. Chen. (2011) Modeling the impact of RV144-like vaccines on HIV transmission. Vaccine 29:36, 6069-6071
311
Nico J.D. Nagelkerke, Jan A.C. Hontelez, Sake J. de Vlas. (2011) The potential impact of an HIV vaccine with limited protection on HIV incidence in Thailand: A modeling study. Vaccine 29:36, 6079-6085
312
Samir K. Lakhashe, Vijayakumar Velu, Gaia Sciaranghella, Nagadenahalli B. Siddappa, Janet M. DiPasquale, Girish Hemashettar, John K. Yoon, Robert A. Rasmussen, Feng Yang, Sandra J. Lee, David C. Montefiori, Francis J. Novembre, François Villinger, Rama Rao Amara, Maria Kahn, Shiu-Lok Hu, Sufen Li, Zhongxia Li, Fred R. Frankel, Marjorie Robert-Guroff, Welkin E. Johnson, Judy Lieberman, Ruth M. Ruprecht. (2011) Prime–boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: Efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine 29:34, 5611-5622
313
Kyeen M. Andersson, A. David Paltiel, Douglas K. Owens. (2011) The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results. Vaccine 29:36, 6107-6112
314
Stephen R Walsh, Raphael Dolin. (2011) Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Review of Vaccines 10:8, 1221-1240
315
Karen Schneider, Cliff C. Kerr, Alexander Hoare, David P. Wilson. (2011) Expected epidemiological impacts of introducing an HIV vaccine in Thailand: A model-based analysis. Vaccine 29:36, 6086-6091
316
B. Ferraro, M. P. Morrow, N. A. Hutnick, T. H. Shin, C. E. Lucke, D. B. Weiner. (2011) Clinical Applications of DNA Vaccines: Current Progress. Clinical Infectious Diseases 53:3, 296-302
317
Paula M. Frew, Matthew Archibald, Brooke Hixson, Carlos del Rio. (2011) Socioecological influences on community involvement in HIV vaccine research. Vaccine 29:36, 6136-6143
318
Sunee Sirivichayakul, Pattarawat Thantiworasit, Pornsupa Chatkulkawin, Supranee Buranapraditkun, Mee Ling Munier, Anthony D. Kelleher, Kiat Ruxrungtham. (2011) Immunogenicity assay validation for an HIV vaccine trial: High IFNγ+/IL-2+ CD8+ T cells background in healthy Thais. Vaccine 29:35, 6002-6007
319
Kyeen M. Andersson, John Stover. (2011) The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand. Vaccine 29:36, 6092-6099
320
Denis R Chopera, Jaclyn K Wright, Mark A Brockman, Zabrina L Brumme. (2011) Immune-mediated attenuation of HIV-1. Future Virology 6:8, 917-928
321
Jan A.C. Hontelez, Nico Nagelkerke, Till Bärnighausen, Roel Bakker, Frank Tanser, Marie-Louise Newell, Mark N. Lurie, Rob Baltussen, Sake J. de Vlas. (2011) The potential impact of RV144-like vaccines in rural South Africa: A study using the STDSIM microsimulation model. Vaccine 29:36, 6100-6106
322
Justin Pollara, Lydia Hart, Faraha Brewer, Joy Pickeral, Beverly Z. Packard, James A. Hoxie, Akira Komoriya, Christina Ochsenbauer, John C. Kappes, Mario Roederer, Ying Huang, Kent J. Weinhold, Georgia D. Tomaras, Barton F. Haynes, David C. Montefiori, Guido Ferrari. (2011) High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry Part A 79A:8, 603-612
323
Rogier W Sanders. (2011) Clinical evaluation of a soluble trimeric HIV-1 envelope glycoprotein vaccine. Expert Review of Vaccines 10:8, 1117-1122
324
Erin E. West, Ben Youngblood, Wendy G. Tan, Hyun-Tak Jin, Koichi Araki, Gabriela Alexe, Bogumila T. Konieczny, Silvia Calpe, Gordon J. Freeman, Cox Terhorst, W. Nicholas Haining, Rafi Ahmed. (2011) Tight Regulation of Memory CD8+ T Cells Limits Their Effectiveness during Sustained High Viral Load. Immunity 35:2, 285-298
325
Richard T. Gray, Mohammad H. Ghaus, Alexander Hoare, David P. Wilson. (2011) Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia. Vaccine 29:36, 6125-6129
326
Robert T. Chen, Dale J. Hu, Eileen Dunne, Michael Shaw, James I. Mullins, Supachai Rerks-Ngarm. (2011) Preparing for the availability of a partially effective HIV vaccine: Some lessons from other licensed vaccines. Vaccine 29:36, 6072-6078
327
D. R. Burton, A. J. Hessell, B. F. Keele, P. J. Klasse, T. A. Ketas, B. Moldt, D. C. Dunlop, P. Poignard, L. A. Doyle, L. Cavacini, R. S. Veazey, J. P. Moore. (2011) Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proceedings of the National Academy of Sciences 108:27, 11181-11186
328
J. A. Hanley. (2011) Measuring Mortality Reductions in Cancer Screening Trials. Epidemiologic Reviews 33:1, 36-45
329
Harry Kaltsidis, Hannah Cheeseman, Jakub Kopycinski, Ambreen Ashraf, Michelle Cashin Cox, Lorna Clark, Insiyah Anjarwalla, Len Dally, Phillip Bergin, Aggeliki Spentzou, Chris Higgs, Frances Gotch, Brian Gazzard, Raul Gomez, Peter Hayes, Peter Kelleher, Dilbinder K. Gill, Jill Gilmour. (2011) Measuring human T cell responses in blood and gut samples using qualified methods suitable for evaluation of HIV vaccine candidates in clinical trials. Journal of Immunological Methods 370:1-2, 43-54
330
Merlin Robb. (2011) HIV vaccine development: a new beginning. Expert Review of Vaccines 10:7, 925-927
331
Bette Korber. (2011) Building on the past to define an efficient path to an HIV vaccine. Expert Review of Vaccines 10:7, 929-931
332
Maarten F. Schim van der Loeff, Alan G. Nyitray, Anna R. Giuliano. (2011) HPV Vaccination to Prevent HIV Infection: Time for Randomized Controlled Trials. Sexually Transmitted Diseases 38:7, 640-643
333
Nancy S Padian, Sandra I McCoy, Salim S Abdool Karim, Nina Hasen, Julia Kim, Michael Bartos, Elly Katabira, Stefano M Bertozzi, Bernhard Schwartländer, Myron S Cohen. (2011) HIV prevention transformed: the new prevention research agenda. The Lancet 378:9787, 269-278
334
L. Lai, S. Kwa, P. A. Kozlowski, D. C. Montefiori, G. Ferrari, W. E. Johnson, V. Hirsch, F. Villinger, L. Chennareddi, P. L. Earl, B. Moss, R. R. Amara, H. L. Robinson. (2011) Prevention of Infection by a Granulocyte-Macrophage Colony-Stimulating Factor Co-Expressing DNA/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine. Journal of Infectious Diseases 204:1, 164-173
335
Anne-Sophie Dugast, Andrew Tonelli, Christoph T. Berger, Margaret E. Ackerman, Gaia Sciaranghella, Qingquan Liu, Magdalena Sips, Ildiko Toth, Alicja Piechocka-Trocha, Musie Ghebremichael, Galit Alter. (2011) Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Virology 415:2, 160-167
336
Laurent Bélec, Mohammad-Ali Jenabian, Charlotte Charpentier, Hela Saïdi. (2011) Combinatorial prevention of HIV transmission in women: the case for a vaginal microbicide. Future Microbiology 6:7, 731-737
337
R. J. Shattock, M. Warren, S. McCormack, C. A. Hankins. (2011) Turning the Tide Against HIV. Science 333:6038, 42-43
338
Luca Cassetta, Guido Poli, Massimo Alfano. HIV and Cytokines. In: Cytokines. Science Publishers, 2011:139-153.
339
Michael M. Thomson, Aurora Fernández-García. (2011) Phylogenetic structure in African HIV-1 subtype C revealed by selective sequential pruning. Virology 415:1, 30-38
340
Donald R Branch. (2011) Role of G protein-coupled vasoactive intestinal peptide receptors in HIV integration. Future Virology 6:6, 741-753
341
S. De Flora, P. Bonanni. (2011) The prevention of infection-associated cancers. Carcinogenesis 32:6, 787-795
342
(2011) Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148). Vaccine 29:25, 4285-4292
343
J. B. F. de Wit, P. Aggleton, T. Myers, M. Crewe. (2011) The rapidly changing paradigm of HIV prevention: time to strengthen social and behavioural approaches. Health Education Research 26:3, 381-392
344
Jean-Louis Excler, Wasima Rida, Frances Priddy, Jill Gilmour, Adrian B. McDermott, Anatoli Kamali, Omu Anzala, Gaudensia Mutua, Eduard J. Sanders, Wayne Koff, Seth Berkley, Patricia Fast. (2011) AIDS Vaccines and Preexposure Prophylaxis: Is Synergy Possible?. AIDS Research and Human Retroviruses 27:6, 669-680
345
Christine S Rollier, Arturo Reyes-Sandoval, Matthew G Cottingham, Katie Ewer, Adrian VS Hill. (2011) Viral vectors as vaccine platforms: deployment in sight. Current Opinion in Immunology 23:3, 377-382
346
Bali Pulendran, Rafi Ahmed. (2011) Immunological mechanisms of vaccination. Nature Immunology 131:6, 509-517
347
Mark W. Hull, Julio Montaner. (2011) Antiretroviral Therapy: A Key Component of a Comprehensive HIV Prevention Strategy. Current HIV/AIDS Reports 8:2, 85-93
348
Tinevimbo Shiri, Alex Welte. (2011) Modelling the impact of acute infection dynamics on the accumulation of HIV-1 mutations. Journal of Theoretical Biology 279:1, 44-54
349
Corie Lok. (2011) Vaccines: His best shot. Nature 473:7348, 439-441
350
Rino Rappuoli, Alan Aderem. (2011) A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 473:7348, 463-469
351
N. L. Letvin, S. S. Rao, D. C. Montefiori, M. S. Seaman, Y. Sun, S.-Y. Lim, W. W. Yeh, M. Asmal, R. S. Gelman, L. Shen, J. B. Whitney, C. Seoighe, M. Lacerda, S. Keating, P. J. Norris, M. G. Hudgens, P. B. Gilbert, A. P. Buzby, L. V. Mach, J. Zhang, H. Balachandran, G. M. Shaw, S. D. Schmidt, J.-P. Todd, A. Dodson, J. R. Mascola, G. J. Nabel. (2011) Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Science Translational Medicine 3:81, 81ra36-81ra36
352
A. W. Chung, G. Isitman, M. Navis, M. Kramski, R. J. Center, S. J. Kent, I. Stratov. (2011) Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proceedings of the National Academy of Sciences 108:18, 7505-7510
353
Brigitte Autran, Benjamin Descours, Véronique Avettand-Fenoel, Christine Rouzioux. (2011) Elite controllers as a model of functional cure. Current Opinion in HIV and AIDS 6:3, 181-187
354
Stanca M. Ciupe, Patrick De Leenheer, Thomas B. Kepler. (2011) Paradoxical suppression of poly-specific broadly neutralizing antibodies in the presence of strain-specific neutralizing antibodies following HIV infection. Journal of Theoretical Biology 277:1, 55-66
355
Amina A. Chaudhry, Gail Berkenblit, Allen L. Gifford, Joseph Cofrancesco, James Sosman, Lynn E. Sullivan. (2011) Update in HIV Medicine for the Generalist. Journal of General Internal Medicine 26:5, 538-542
356
Filippos Porichis, Daniel E Kaufmann. (2011) HIV-specific CD4 T cells and immune control of viral replication. Current Opinion in HIV and AIDS 6:3, 174-180
357
B. J. Flynn, K. Kastenmuller, U. Wille-Reece, G. D. Tomaras, M. Alam, R. W. Lindsay, A. M. Salazar, B. Perdiguero, C. E. Gomez, R. Wagner, M. Esteban, C. G. Park, C. Trumpfheller, T. Keler, G. Pantaleo, R. M. Steinman, R. Seder. (2011) Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proceedings of the National Academy of Sciences 108:17, 7131-7136
358
Arman A. Bashirova, Rasmi Thomas, Mary Carrington. (2011) HLA/KIR Restraint of HIV: Surviving the Fittest. Annual Review of Immunology 29:1, 295-317
359
L. Corey, G. J. Nabel, C. Dieffenbach, P. Gilbert, B. F. Haynes, M. Johnston, J. Kublin, H. C. Lane, G. Pantaleo, L. J. Picker, A. S. Fauci. (2011) HIV-1 Vaccines and Adaptive Trial Designs. Science Translational Medicine 3:79, 79ps13-79ps13
360
P. Spearman, M. A. Lally, M. Elizaga, D. Montefiori, G. D. Tomaras, M. J. McElrath, J. Hural, S. C. De Rosa, A. Sato, Y. Huang, S. E. Frey, P. Sato, J. Donnelly, S. Barnett, L. J. Corey, . (2011) A Trimeric, V2-Deleted HIV-1 Envelope Glycoprotein Vaccine Elicits Potent Neutralizing Antibodies but Limited Breadth of Neutralization in Human Volunteers. Journal of Infectious Diseases 203:8, 1165-1173
361
V. DeGruttola, R. T. Schooley. (2011) Antiretroviral Therapy as Prevention: Linking the Mainframe to Main Street. Clinical Infectious Diseases 52:8, 1050-1052
362
Agostino Riva, Elisa Vicenzi, Massimo Galli, Guido Poli. (2011) Strenuous resistance to natural HIV-1 disease progression: viral controllers and long-term nonprogressors. Future Virology 6:4, 521-533
363
Marta L. Marthas, Koen K.A. Van Rompay, Zachary Abbott, Patricia Earl, Linda Buonocore-Buzzelli, Bernard Moss, Nina F. Rose, John K. Rose, Pamela A. Kozlowski, Kristina Abel. (2011) Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques. Vaccine 29:17, 3124-3137
364
Niamh Keane, Mina John. (2011) Biomarkers of natural and vaccine immunity against HIV. Biomarkers in Medicine 5:2, 113-116
365
Amy W. Chung, Marjon Navis, Gamze Isitman, Rob Centre, Robert Finlayson, Mark Bloch, Linda Gelgor, Antony Kelleher, Stephen J Kent, Ivan Stratov. (2011) Activation of NK Cells by ADCC Responses During Early HIV Infection. Viral Immunology 24:2, 171-175
366
Ian McGowan. (2011) Rectal Microbicides: Can We Make Them and Will People Use Them?. AIDS and Behavior 15:S1, 66-71
367
P. B. Gilbert, J. O. Berger, D. Stablein, S. Becker, M. Essex, S. M. Hammer, J. H. Kim, V. G. DeGruttola. (2011) Statistical Interpretation of the RV144 HIV Vaccine Efficacy Trial in Thailand: A Case Study for Statistical Issues in Efficacy Trials. Journal of Infectious Diseases 203:7, 969-975
368
D. W. Fitzgerald, H. Janes, M. Robertson, R. Coombs, I. Frank, P. Gilbert, M. Loufty, D. Mehrotra, A. Duerr, . (2011) An Ad5-Vectored HIV-1 Vaccine Elicits Cell-mediated Immunity but does not Affect Disease Progression in HIV-1-infected Male Subjects: Results From a Randomized Placebo-Controlled Trial (The Step Study). Journal of Infectious Diseases 203:6, 765-772
369
Edward L. Korn, Boris Freidlin. (2011) Inefficacy Interim Monitoring Procedures in Randomized Clinical Trials: The Need to Report. The American Journal of Bioethics 11:3, 2-10
370
Ouzama Nicholson, Fay DiCandilo, James Kublin, Xiao Sun, Erin Quirk, Michelle Miller, Glenda Gray, Jean Pape, Michael N. Robertson, Devan V. Mehrotra, Steven Self, Katherine Turner, Jorge Sanchez, Punnee Pitisuttithum, Ann Duerr, Sheri Dubey, Lisa Kierstead, Danilo Casimiro, Scott M. Hammer. (2011) Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. AIDS Research and Human Retroviruses110306081558090
371
Marco Salemi. (2011) Toward a robust monitoring of HIV subtypes distribution worldwide. AIDS 25:5, 713-714
372
Gamze Isitman, Amy W. Chung, Marjon Navis, Stephen J. Kent, Ivan Stratov. (2011) Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology 412:1, 110-116
373
Ume L Abbas. (2011) Uptake of biomedical interventions for prevention of sexually transmitted HIV. Current Opinion in HIV and AIDS 6:2, 114-118
374
Ann E. Kurth, Connie Celum, Jared M. Baeten, Sten H. Vermund, Judith N. Wasserheit. (2011) Combination HIV Prevention: Significance, Challenges, and Opportunities. Current HIV/AIDS Reports 8:1, 62-72
375
P. A. Goepfert, M. L. Elizaga, A. Sato, L. Qin, M. Cardinali, C. M. Hay, J. Hural, S. C. DeRosa, O. D. DeFawe, G. D. Tomaras, D. C. Montefiori, Y. Xu, L. Lai, S. A. Kalams, L. R. Baden, S. E. Frey, W. A. Blattner, L. S. Wyatt, B. Moss, H. L. Robinson, . (2011) Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles. Journal of Infectious Diseases 203:5, 610-619
376
Joris Hemelaar, Eleanor Gouws, Peter D Ghys, Saladin Osmanov. (2011) Global trends in molecular epidemiology of HIV-1 during 2000–2007. AIDS 25:5, 679-689
377
Danushka K Wijesundara, Ronald J Jackson, Ian A Ramshaw, Charani Ranasinghe. (2011) Human immunodeficiency virus-1 vaccine design: where do we go now?. Immunology and Cell Biology 89:3, 367-374
378
E.A. McLaughlin, R.J. Aitken. (2011) Is there a role for immunocontraception?. Molecular and Cellular Endocrinology 335:1, 78-88
379
Ashley T. Haase. (2011) Early Events in Sexual Transmission of HIV and SIV and Opportunities for Interventions. Annual Review of Medicine 62:1, 127-139
380
E. Van Braeckel, P. Bourguignon, M. Koutsoukos, F. Clement, M. Janssens, I. Carletti, A. Collard, M.-A. Demoitie, G. Voss, G. Leroux-Roels, L. McNally. (2011) An Adjuvanted Polyprotein HIV-1 Vaccine Induces Polyfunctional Cross-Reactive CD4+ T Cell Responses in Seronegative Volunteers. Clinical Infectious Diseases 52:4, 522-531
381
M. Juliana McElrath. (2011) Standing Guard at the Mucosa. Immunity 34:2, 146-148
382
Marcio O Lasaro, Larissa H Haut, Xiangyang Zhou, Zhiquan Xiang, Dongming Zhou, Yan Li, Wynetta Giles-Davis, Hua Li, Jessica C Engram, Lauren J DiMenna, Ang Bian, Marina Sazanovich, Elizabeth M Parzych, Raj Kurupati, Juliana C Small, Te-Lang Wu, Rachel M Leskowitz, Nicole R Klatt, Jason M Brenchley, David A Garber, Mark Lewis, Sarah J Ratcliffe, Michael R Betts, Guido Silvestri, Hildegund C Ertl. (2011) Vaccine-induced T cells Provide Partial Protection Against High-dose Rectal SIVmac239 Challenge of Rhesus Macaques. Molecular Therapy 19:2, 417-426
383
Mauricio A. Arias, Andrew Loxley, Christy Eatmon, Griet Van Roey, David Fairhurst, Mark Mitchnick, Philip Dash, Tom Cole, Frank Wegmann, Quentin Sattentau, Robin Shattock. (2011) Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen. Vaccine 29:6, 1258-1269
384
Ioannis Hodges-Mameletzis, GJ De Bree, Sarah L Rowland-Jones. (2011) An underestimated lentivirus model: what can HIV-2 research contribute to the development of an effective HIV-1 vaccine?. Expert Review of Anti-infective Therapy 9:2, 195-206
385
Christopher Lai-Hipp, Tiffany Goldberg, Edward Scott, Alyssa Ziman, Girish Vyas. (2011) Pooled peripheral blood mononuclear cells provide an optimized cellular substrate for human immunodeficiency virus Type 1 isolation during acute infection. Transfusion 51:2, 333-337
386
Barton F. Haynes, M. Anthony Moody, Hua-Xin Liao, Laurent Verkoczy, Georgia D. Tomaras. (2011) B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends in Molecular Medicine 17:2, 108-116
387
Morgane Bomsel, Daniela Tudor, Anne-Sophie Drillet, Annette Alfsen, Yonatan Ganor, Marie-Gaëlle Roger, Nicolas Mouz, Mario Amacker, Anick Chalifour, Lorenzo Diomede, Gilles Devillier, Zhe Cong, Qiang Wei, Hong Gao, Chuan Qin, Gui-Bo Yang, Rinaldo Zurbriggen, Lucia Lopalco, Sylvain Fleury. (2011) Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges. Immunity 34:2, 269-280
388
Andrea R. Thurman, Gustavo F. Doncel. (2011) Innate Immunity and Inflammatory Response to Trichomonas vaginalis and Bacterial Vaginosis: Relationship to HIV Acquisition. American Journal of Reproductive Immunology 65:2, 89-98
389
Vivek Naranbhai, Quarraisha Abdool Karim, Anna Meyer-Weitz, Vivek Naranbhai. Interventions to modify sexual risk behaviours for preventing HIV in homeless youth. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2011.
390
Stuart N. Isaacs. (2011) A stimulating way to improve T cell responses to poxvirus-vectored vaccines. Journal of Clinical Investigation 121:1, 19-21
391
Jeffrey R Currier, Merlin L Robb, Nelson L Michael, Mary A Marovich. (2011) Defining epitope coverage requirements for T cell-based HIV vaccines: Theoretical considerations and practical applications. Journal of Translational Medicine 9:1, 212
392
Richard G Wamai, Brian J Morris, Stefan A Bailis, David Sokal, Jeffrey D Klausner, Ross Appleton, Nelson Sewankambo, David A Cooper, John Bongaarts, Guy de Bruyn, Alex D Wodak, Joya Banerjee. (2011) Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa. Journal of the International AIDS Society 14:1, 49
393
C. Semaille, F. Lot, J. Pillonel, F. Cazein. (2011) Épidémiologie, transmission et prévention de l'infection à VIH. EMC - Maladies infectieuses 8:1, 1-10
394
Luigi Buonaguro, Bali Pulendran. (2011) Immunogenomics and systems biology of vaccines. Immunological Reviews 239:1, 197-208
395
Kazuhiro Matsuo, Yasuhiro Yasutomi. (2011) Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control. Tuberculosis Research and Treatment 2011, 1-9
396
Sarah Brinckmann, Kelly da Costa, Marit J van Gils, David Hallengärd, Katja Klein, Luisa Madeira, Lara Mainetti, Paolo Palma, Katharina Raue, David Reinhart, Marc Reudelsterz, Nicolas Ruffin, Janna Seifried, Katrein Schäfer, Enas Sheik-Khalil, Annette Sköld, Hannes Uchtenhagen, Nicolas Vabret, Serena Ziglio, Gabriella Scarlatti, Robin Shattock, Britta Wahren, Frances Gotch. (2011) Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010. Journal of Translational Medicine 9:1, 40
397
Lori L. Heise, Charlotte Watts, Anna Foss, James Trussell, Peter Vickerman, Richard Hayes, Sheena McCormack. (2011) Apples and oranges? Interpreting success in HIV prevention trials. Contraception 83:1, 10-15
398
Wibke Bayer, Ruth Lietz, Teona Ontikatze, Lena Johrden, Matthias Tenbusch, Ghulam Nabi, Simone Schimmer, Peter Groitl, Hans Wolf, Cassandra M Berry, Klaus Überla, Ulf Dittmer, Oliver Wildner. (2011) Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes. Retrovirology 8:1, 75
399
David Hallengärd, B. Kristian Haller, Sarah Petersson, Andreas Boberg, Anna-Karin Maltais, Maria Isaguliants, Britta Wahren, Andreas Bråve. (2011) Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity. Vaccine 29:4, 839-848
400
Simon H Bridge, Sally A Sharpe, Mike J Dennis, Stuart D Dowall, Brian Getty, Donald S Anson, Michael A Skinner, James P Stewart, Tom J Blanchard. (2011) Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles. Virology Journal 8:1, 429
401
Ingo Jordan, Stefan Northoff, Michael Thiele, Stefan Hartmann, Deborah Horn, Kristin Höwing, Holger Bernhardt, Stefanie Oehmke, Henning von Horsten, Dierk Rebeski, Lars Hinrichsen, Vladimir Zelnik, Wiebke Mueller, Volker Sandig. (2011) A chemically defined production process for highly attenuated poxviruses. Biologicals 39:1, 50-58
402
Elizabeth K Nelson, Britt Piehler, Josh Eckels, Adam Rauch, Matthew Bellew, Peter Hussey, Sarah Ramsay, Cory Nathe, Karl Lum, Kevin Krouse, David Stearns, Brian Connolly, Tom Skillman, Mark Igra. (2011) LabKey Server: An open source platform for scientific data integration, analysis and collaboration. BMC Bioinformatics 12:1, 71
403
Paul Shapshak, Pandjassarame Kangueane, Robert K Fujimura, Deborah Commins, Francesco Chiappelli, Elyse Singer, Andrew J Levine, Alireza Minagar, Francis J Novembre, Charurut Somboonwit, Avindra Nath, John T Sinnott. (2011) Editorial NeuroAIDS review. AIDS 25:2, 123-141
404
P.A. Newman, S. Yim, A. Daley, R. Walisser, R. Halpenny, W. Cunningham, M. Loutfy. (2011) “Once Bitten, Twice Shy”: Participant perspectives in the aftermath of an early HIV vaccine trial termination. Vaccine 29:3, 451-458
405
A. D. Cristillo, M. G. Ferrari, L. Hudacik, B. Lewis, L. Galmin, B. Bowen, D. Thompson, N. Petrovsky, P. Markham, R. Pal. (2011) Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. Journal of General Virology 92:1, 128-140
406
Kathleen M MacQueen. (2011) Framing the social in biomedical HIV prevention trials: a 20-year retrospective. Journal of the International AIDS Society 14:Suppl 2, S3
407
Laura Papagno, Galit Alter, Lambert Assoumou, Robert L Murphy, Felipe Garcia, Bonaventura Clotet, Martin Larsen, Martine Braibant, Anne-Geneviève Marcelin, Dominique Costagliola, Marcus Altfeld, Christine Katlama, Brigitte Autran. (2011) Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS 25:1, 27-36
408
Nathan Ford, Alexandra Calmy, Edward J Mills. (2011) The first decade of antiretroviral therapy in Africa. Globalization and Health 7:1, 33
409
Yen-Ju Shen, Enid Shephard, Nicola Douglass, Nicolette Johnston, Craig Adams, Carolyn Williamson, Anna-Lise Williamson. (2011) A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV). Virology Journal 8:1, 265
410
Beatriz Mothe, Anuska Llano, Javier Ibarrondo, Marcus Daniels, Cristina Miranda, Jennifer Zamarreño, Vanessa Bach, Rosario Zuniga, Susana Pérez-Álvarez, Christoph T Berger, Maria C Puertas, Javier Martinez-Picado, Morgane Rolland, Marilu Farfan, James J Szinger, William H Hildebrand, Otto O Yang, Victor Sanchez-Merino, Chanson J Brumme, Zabrina L Brumme, David Heckerman, Todd M Allen, James I Mullins, Guadalupe Gómez, Philip J Goulder, Bruce D Walker, Jose M Gatell, Bonaventura Clotet, Bette T Korber, Jorge Sanchez, Christian Brander. (2011) Definition of the viral targets of protective HIV-1-specific T cell responses. Journal of Translational Medicine 9:1, 208
411
George Makedonas, Michael R. Betts. (2011) Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV. Immunological Reviews 239:1, 109-124
412
Meritxell Genescà. (2011) Characterization of an Effective CTL Response against HIV and SIV Infections. Journal of Biomedicine and Biotechnology 2011, 1-9
413
Michael , Nelson L. , . (2010) Oral Preexposure Prophylaxis for HIV — Another Arrow in the Quiver?. New England Journal of Medicine 363:27, 2663-2665
Free Full Text414
Tara G. Edmonds, Haitao Ding, Xing Yuan, Qing Wei, Kendra S. Smith, Joan A. Conway, Lindsay Wieczorek, Bruce Brown, Victoria Polonis, John T. West, David C. Montefiori, John C. Kappes, Christina Ochsenbauer. (2010) Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 408:1, 1-13
415
Gary Frey, Jia Chen, Sophia Rits-Volloch, Michael M Freeman, Susan Zolla-Pazner, Bing Chen. (2010) Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nature Structural & Molecular Biology 17:12, 1486-1491
416
Sally L Hodder, Jessica Justman, Danielle F Haley, Adaora A Adimora, Catherine I Fogel, Carol E Golin, Ann OʼLeary, Lydia Soto-Torres, Gina Wingood, Wafaa M El-Sadr. (2010) Challenges of a Hidden Epidemic: HIV Prevention Among Women in the United States. JAIDS Journal of Acquired Immune Deficiency Syndromes 55, S69-S73
417
Barb Lohman-Payne, Jennifer Slyker, Sarah L. Rowland-Jones. (2010) Immune-based Approaches to the Prevention of Mother-to-child Transmission of HIV-1: Active and Passive Immunization. Clinics in Perinatology 37:4, 787-805
418
Gregorio A Millett, Jeffrey S Crowley, Howard Koh, Ronald O Valdiserri, Thomas Frieden, Carl W Dieffenbach, Kevin A. Fenton, Regina Benjamin, Jack Whitescarver, Jonathan Mermin, Deborah Parham-Hopson, Anthony S Fauci. (2010) A Way Forward: The National HIV/AIDS Strategy and Reducing HIV Incidence in the United States. JAIDS Journal of Acquired Immune Deficiency Syndromes 55, S144-S147
419
Susan M Fetherston, R Karl Malcolm, A David Woolfson. (2010) Controlled-release vaginal ring drug-delivery systems: a key strategy for the development of effective HIV microbicides. Therapeutic Delivery 1:6, 785-802
420
J. Ambrosioni, G. Andreani, C. Acuipil, R. Barral, R. Rabinovich, Liliana Martinez Peralta. (2010) Comparative reactivity of serum samples from Argentinean HIV-infected patients with V3 peptides from subtype B or BF recombinants. Archives of Virology 155:12, 2029-2034
421
Philip L. Bulterys, Sudeb C. Dalai, David A. Katzenstein. (2010) Viral Sequence Analysis from HIV-Infected Mothers and Infants: Molecular Evolution, Diversity, and Risk Factors for Mother-To-Child Transmission. Clinics in Perinatology 37:4, 739-750
422
A. Mader, R. Kunert. (2010) Humanization strategies for an anti-idiotypic antibody mimicking HIV-1 gp41. Protein Engineering Design and Selection 23:12, 947-954
423
Jonathan D Fuchs, Magda E Sobieszczyk, Scott M Hammer, Susan P Buchbinder. (2010) Lessons Drawn From Recent HIV Vaccine Efficacy Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes 55, S128-S131
424
Michael M. Freeman, Michael S. Seaman, Sophia Rits-Volloch, Xinguo Hong, Chia-Ying Kao, David D. Ho, Bing Chen. (2010) Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody. Structure 18:12, 1632-1641
425
Geetha P. Bansal, Wolfgang W. Leitner. (2010) Innate immunity in HIV infection and implications for vaccine design: A summary of the workshop held at the National Institute of Allergy and Infectious Diseases, Bethesda on February 25–26, 2010. Vaccine 28:52, 8229-8235
426
Damien Z Soghoian, Hendrik Streeck. (2010) Cytolytic CD4 + T cells in viral immunity. Expert Review of Vaccines 9:12, 1453-1463
427
H. Dreja, E. O'Sullivan, C. Pade, K. M. Greene, H. Gao, K. Aubin, J. Hand, A. Isaksen, C. D'Souza, W. Leber, D. Montefiori, M. S. Seaman, J. Anderson, C. Orkin, A. McKnight. (2010) Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. Journal of General Virology 91:11, 2794-2803
428
M R Nicol, A D M Kashuba. (2010) Pharmacologic Opportunities for HIV Prevention. Clinical Pharmacology & Therapeutics 88:5, 598-609
429
Antonella Caivano, Nicole A. Doria-Rose, Benjamin Buelow, Rossella Sartorius, Maria Trovato, Luciana D'Apice, Gonzalo J. Domingo, William F. Sutton, Nancy L. Haigwood, Piergiuseppe De Berardinis. (2010) HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells. Virology 407:2, 296-305
430
Peter S. Kim, Sarah W. Read. (2010) Nanotechnology and HIV: potential applications for treatment and prevention. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 2:6, 693-702
431
Shirui Li, Xiangrong Qi, Yingying Gao, Yanling Hao, Lianxian Cui, Li Ruan, Wei He. (2010) IL-15 increases the frequency of effector memory CD8+ T cells in rhesus monkeys immunized with HIV vaccine. Cellular and Molecular Immunology 7:6, 491-494
432
George B Cohen. (2010) HIV vaccines: sin boldly!. AIDS 24:18, 2877-2879
433
Margaret A. Liu. (2010) Immunologic Basis of Vaccine Vectors. Immunity 33:4, 504-515
434
Philip Hunter. (2010) Vaccine outlooks. EMBO reports 11:10, 738-741
435
Jonathan Weber, Roger Tatoud, Sarah Fidler. (2010) Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission. AIDS 24:Suppl 4, S27-S39
436
John M Kaldor, David P Wilson. (2010) How low can you go: the impact of a modestly effective HIV vaccine compared with male circumcision. AIDS 24:16, 2573-2578
437
M. Juliana McElrath, Barton F. Haynes. (2010) Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination. Immunity 33:4, 542-554
438
Yue Sun, Sampa Santra, Adam P. Buzby, John R. Mascola, Gary J. Nabel, Norman L. Letvin. (2010) Recombinant vector-induced HIV/SIV-specific CD4+ T lymphocyte responses in rhesus monkeys. Virology 406:1, 48-55
439
Isabel Leroux-Roels, Marguerite Koutsoukos, Frédéric Clement, Sophia Steyaert, Michel Janssens, Patricia Bourguignon, Kristen Cohen, Marcus Altfeld, Pierre Vandepapelière, Louise Pedneault, Lisa McNally, Geert Leroux-Roels, Gerald Voss. (2010) Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. Vaccine 28:43, 7016-7024
440
Z Mike Chirenje, Jeanne Marrazzo, Urvi M Parikh. (2010) Antiretroviral-based HIV prevention strategies for women. Expert Review of Anti-infective Therapy 8:10, 1177-1186
441
Catherine A Hankins, Barbara O de Zalduondo. (2010) Combination prevention: a deeper understanding of effective HIV prevention. AIDS 24:Suppl 4, S70-S80
442
Carlo Zanotto, Eleana Pozzi, Sole Pacchioni, Luca Volonté, Carlo De Giuli Morghen, Antonia Radaelli. (2010) Canarypox and fowlpox viruses as recombinant vaccine vectors: A biological and immunological comparison. Antiviral Research 88:1, 53-63
443
Kuan-Hsiang G. Huang, David Bonsall, Aris Katzourakis, Emma C. Thomson, Sarah J. Fidler, Janice Main, David Muir, Jonathan N. Weber, Alexander J. Frater, Rodney E. Phillips, Oliver G. Pybus, Philip J.R. Goulder, Myra O. McClure, Graham S. Cooke, Paul Klenerman. (2010) B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nature Communications 1:7, 102
444
Gambo Aliyu, Mukhtar Mohammad, Ahmed Saidu, Prosanta Mondal, Man Charurat, Alash'le Abimiku, Abdulsalami Nasidi, William Blattner. (2010) HIV infection awareness and willingness to participate in future HIV vaccine trials across different risk groups in Abuja, Nigeria. AIDS Care 22:10, 1277-1284
445
Richard Hayes, Saidi Kapiga, Nancy Padian, Sheena McCormack, Judith Wasserheit. (2010) HIV prevention research: taking stock and the way forward. AIDS 24:Suppl 4, S81-S92
446
Ronald N. Germain. (2010) Vaccines and the Future of Human Immunology. Immunity 33:4, 441-450
447
Patricia E Fast, Pontiano Kaleebu. (2010) HIV vaccines: current status worldwide and in Africa. AIDS 24:Suppl 4, S50-S60
448
Q. Abdool Karim, S. S. Abdool Karim, J. A. Frohlich, A. C. Grobler, C. Baxter, L. E. Mansoor, A. B. M. Kharsany, S. Sibeko, K. P. Mlisana, Z. Omar, T. N. Gengiah, S. Maarschalk, N. Arulappan, M. Mlotshwa, L. Morris, D. Taylor, . (2010) Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science 329:5996, 1168-1174
449
Maxim Totrov, Xunqing Jiang, Xiang-Peng Kong, Sandra Cohen, Chavdar Krachmarov, Aidy Salomon, Constance Williams, Michael S. Seaman, Timothy Cardozo, Miroslaw K. Gorny, Shixia Wang, Shan Lu, Abraham Pinter, Susan Zolla-Pazner. (2010) Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Virology 405:2, 513-523
450
Tomáš Hanke. (2010) On the growing complexity of HIV-1 vaccines. HIV Therapy 4:5, 543-552
451
Giuseppe Pantaleo, Mariano Esteban, Bertram Jacobs, Jim Tartaglia. (2010) Poxvirus vector-based HIV vaccines. Current Opinion in HIV and AIDS 5:5, 391-396
452
Barton F Haynes, Hua-Xin Liao, Georgia D Tomaras. (2010) Is developing an HIV-1 vaccine possible?. Current Opinion in HIV and AIDS 5:5, 362-367
453
Georgia D Tomaras, Barton F Haynes. (2010) Strategies for eliciting HIV-1 inhibitory antibodies. Current Opinion in HIV and AIDS 5:5, 421-427
454
Silvija I Staprans, Mark B Feinberg, John W Shiver, Danilo R Casimiro. (2010) Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective. Current Opinion in HIV and AIDS 5:5, 377-385
455
Jerome H Kim, Supachai Rerks-Ngarm, Jean-Louis Excler, Nelson L Michael. (2010) HIV vaccines: lessons learned and the way forward. Current Opinion in HIV and AIDS 5:5, 428-434
456
Hélène Perrin, Glenda Canderan, Rafick-Pierre Sékaly, Lydie Trautmann. (2010) New approaches to design HIV-1 T-cell vaccines. Current Opinion in HIV and AIDS 5:5, 368-376
457
Seth Berkley, Kenneth Bertram, Jean-François Delfraissy, Ruxandra Draghia-Akli, Anthony Fauci, Cynthia Hallenbeck, Madame Jeannette Kagame, Peter Kim, Daisy Mafubelu, Malegapuru W Makgoba, Peter Piot, Mark Walport, Mitchell Warren, Tadataka Yamada, José Esparza, Catherine Hankins, Margaret I Johnston, Yves Lévy, Manuel Romaris, Rafi Ahmed, Alan Bernstein. (2010) The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise. Nature Medicine 16:9, 981-989
458
Yegor Voronin, Amapola Manrique, Alan Bernstein. (2010) The future of HIV vaccine research and the role of the Global HIV Vaccine Enterprise. Current Opinion in HIV and AIDS 5:5, 414-420
459
Yegor Voronin, Sanjay Phogat. (2010) HIV/AIDS: vaccines and alternate strategies for treatment and prevention. Annals of the New York Academy of Sciences 1205, E1-E9
460
Sudhir Paul, Stephanie Planque, Yasuhiro Nishiyama, Miguel Escobar, Carl Hanson. (2010) Back to the future: covalent epitope-based HIV vaccine development. Expert Review of Vaccines 9:9, 1027-1043
461
Dominique Salmon-Céron, Christine Durier, Corinne Desaint, Lise Cuzin, Mathieu Surenaud, Nadine Ben Hamouda, Jean-Daniel Lelièvre, Bénédicte Bonnet, Gilles Pialoux, Isabelle Poizot-Martin, Jean-Pierre Aboulker, Yves Lévy, Odile Launay. (2010) Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. AIDS 24:14, 2211-2223
462
Robert M Paris, Jerome H Kim, Merlin L Robb, Nelson L Michael. (2010) Prime–boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Review of Vaccines 9:9, 1055-1069
463
Harel Dahari, Stephen M. Feinstone, Marian E. Major. (2010) Meta-Analysis of Hepatitis C Virus Vaccine Efficacy in Chimpanzees Indicates an Importance for Structural Proteins. Gastroenterology 139:3, 965-974
464
Ann Duerr. (2010) Update on mucosal HIV vaccine vectors. Current Opinion in HIV and AIDS 5:5, 397-403
465
Kazuhiro Matsuo, Naoki Yamamoto. (2010) Paradigm change in immune correlation: cellular or humoral?. Expert Review of Vaccines 9:9, 985-987
466
Béatris Mastelic, Sohail Ahmed, William M. Egan, Giuseppe Del Giudice, Hana Golding, Ian Gust, Pieter Neels, Steven G. Reed, Rebecca L. Sheets, Claire-Anne Siegrist, Paul-Henri Lambert. (2010) Mode of action of adjuvants: Implications for vaccine safety and design. Biologicals 38:5, 594-601
467
Daniela Teixeira, Patricia Munerato, Shirley Cavalcante Vasconcelos Komninakis, Erika Etsuko Fusuma, Luiz Mario Janini, Maria Cecilia Araripe Sucupira, Ricardo Sobhie Diaz. (2010) The Detection of in Vivo and in Vitro HIV Type 1 B/F Profiles in Brazil Using a Real-Time PCR Assay for Five HIV Type 1 Genomic Regions. AIDS Research and Human Retroviruses 26:9, 981-990
468
Dan H Barouch. (2010) Novel adenovirus vector-based vaccines for HIV-1. Current Opinion in HIV and AIDS 5:5, 386-390
469
Monica Vaccari, Poonam Poonam, Genoveffa Franchini. (2010) Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Review of Vaccines 9:9, 997-1005
470
Joseph G Joyce, Jan ter Meulen. (2010) Pushing the envelope on HIV-1 neutralization. Nature Biotechnology 28:9, 929-931
471
C. Sundling, M. N. E. Forsell, S. O'Dell, Y. Feng, B. Chakrabarti, S. S. Rao, K. Lore, J. R. Mascola, R. T. Wyatt, I. Douagi, G. B. Karlsson Hedestam. (2010) Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. Journal of Experimental Medicine 207:9, 2003-2017
472
K. J. Doores, C. Bonomelli, D. J. Harvey, S. Vasiljevic, R. A. Dwek, D. R. Burton, M. Crispin, C. N. Scanlan. (2010) Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proceedings of the National Academy of Sciences 107:31, 13800-13805
473
Nunzia Scotti, Luigi Buonaguro, Maria Lina Tornesello, Teodoro Cardi, Franco Maria Buonaguro. (2010) Plant-based anti-HIV-1 strategies: vaccine molecules and antiviral approaches. Expert Review of Vaccines 9:8, 925-936
474
Ralph M. Steinman. (2010) Some active areas of DC research and their medical potential. European Journal of Immunology 40:8, 2085-2088
475
Anatoli Kamali. (2010) What is new in HIV/AIDS research in developing countries?. Tropical Medicine & International Health 15:8, 975-980
476
Fred Zepp. (2010) Principles of vaccine design—Lessons from nature. Vaccine 28, C14-C24
477
Koff , Wayne C. , Berkley , Seth F. , . (2010) The Renaissance in HIV Vaccine Development — Future Directions. New England Journal of Medicine 363:5,
Free Full Text478
Cassandra Willyard. (2010) Tiny steps towards an HIV vaccine. Nature 466:7304, S8-S8
479
Susan Zolla-Pazner, Timothy Cardozo. (2010) Structure–function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nature Reviews Immunology 10:7, 527-535
480
Brandon F Keele. (2010) Identifying and characterizing recently transmitted viruses. Current Opinion in HIV and AIDS 5:4, 327-334
481
Bret J Rudy, Bill G Kapogiannis, Michelle A Lally, Glenda E Gray, Linda-Gail Bekker, Paul Krogstad, Ian McGowan. (2010) Youth-Specific Considerations in the Development of Preexposure Prophylaxis, Microbicide, and Vaccine Research Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes 54, S31-S42
482
Olamide Dosekun, Julie Fox. (2010) An overview of the relative risks of different sexual behaviours on HIV transmission. Current Opinion in HIV and AIDS 5:4, 291-297
483
Carol A. Marzetta, Stephen S. Lee, Sandra J. Wrobel, Kanwarjit J. Singh, Nina Russell, José Esparza. (2010) The potential global market size and public health value of an HIV-1 vaccine in a complex global market. Vaccine 28:30, 4786-4797
484
Eric Y Wong, Indira K Hewlett. (2010) HIV diagnostics: challenges and opportunities. HIV Therapy 4:4, 399-412
485
Reuben Granich, Siobhan Crowley, Marco Vitoria, Caoimhe Smyth, James G Kahn, Rod Bennett, Ying-Ru Lo, Yves Souteyrand, Brian Williams. (2010) Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Current Opinion in HIV and AIDS 5:4, 298-304
486
Jose J Reina, Anna Bernardi, Mario Clerici, Javier Rojo. (2010) HIV microbicides: state-of-the-art and new perspectives on the development of entry inhibitors. Future Medicinal Chemistry 2:7, 1141-1159
487
Myron S Cohen, Sarah Fidler. (2010) HIV prevention 2010: where are we now and where are we going?. Current Opinion in HIV and AIDS 5:4, 265-268
488
Sacha Gnjatic, Nikhil B. Sawhney, Nina Bhardwaj. (2010) Toll-Like Receptor Agonists. The Cancer Journal 16:4, 382-391
489
Bill G Kapogiannis, Ed Handelsman, Monica S Ruiz, Sonia Lee. (2010) Introduction: Paving the Way for Biomedical HIV Prevention Interventions in Youth. JAIDS Journal of Acquired Immune Deficiency Syndromes 54, S1-S4
490
Peter A Newman, Carmen Logie. (2010) HIV vaccine acceptability: a systematic review and meta-analysis. AIDS 24:11, 1749-1756
491
George K Lewis. (2010) Challenges of antibody-mediated protection against HIV-1. Expert Review of Vaccines 9:7, 683-687
492
Stephen D Barr. (2010) Cellular HIV-1 restriction factors: a new avenue for AIDS therapy?. Future Virology 5:4, 417-433
493
E. Bianchi, J. G. Joyce, M. D. Miller, A. C. Finnefrock, X. Liang, M. Finotto, P. Ingallinella, P. McKenna, M. Citron, E. Ottinger, R. W. Hepler, R. Hrin, D. Nahas, C. Wu, D. Montefiori, J. W. Shiver, A. Pessi, P. S. Kim. (2010) Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proceedings of the National Academy of Sciences 107:23, 10655-10660
494
Rupert Kaul, Kelly S MacDonald, Nico J Nagelkerke, Joshua Kimani, Keith Fowke, T Blake Ball, Ma Luo, Anthony Kariri, Walter Jaoko, Stephen Moses, Sarah Rowland-Jones, Francis A Plummer. (2010) HIV viral set point and host immune control in individuals with HIV-specific CD8+ T-cell responses prior to HIV acquisition. AIDS 24:10, 1449-1454
495
Hildegund CJ Ertl, Antonio Lanzavecchia. (2010) Introduction. Current Opinion in Immunology 22:3, 355-357
496
Adi Moseri, Subramanyam Tantry, Yael Sagi, Boris Arshava, Fred Naider, Jacob Anglister. (2010) An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120. Virology 401:2, 293-304
497
Laura M Walker, Dennis R Burton. (2010) Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Current Opinion in Immunology 22:3, 358-366
498
Anna Laura Ross, Andreas Bråve, Gabriella Scarlatti, Amapola Manrique, Luigi Buonaguro. (2010) Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. The Lancet Infectious Diseases 10:5, 305-316
499
Barton F Haynes, Nathan I Nicely, S Munir Alam. (2010) HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention?. Nature Structural & Molecular Biology 17:5, 543-545
500
Vicky Jespers, Ali M Harandi, Jorma Hinkula, Donata Medaglini, Roger Le Grand, Christiane Stahl-Hennig, Willy Bogers, Raphaelle El Habib, Frank Wegmann, Carol Fraser, Martin Cranage, Robin J Shattock, Anna-Lena Spetz. (2010) Assessment of mucosal immunity to HIV-1. Expert Review of Vaccines 9:4, 381-394
501
A. L. Goodman, S. J. Draper. (2010) Blood-stage malaria vaccines — recent progress and future challenges. Annals of Tropical Medicine and Parasitology 104:3, 189-211
502
Wayne C. Koff. (2010) Accelerating HIV vaccine development. Nature 464:7286, 161-162
503
Herbert W. Virgin, Bruce D. Walker. (2010) Immunology and the elusive AIDS vaccine. Nature 464:7286, 224-231
504
Ashley T. Haase. (2010) Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464:7286, 217-223
505
George B Cohen. (2010) Mechanism of protection of live attenuated simian immunodeficiency virus: coevolution of viral and immune responses. AIDS 24:5, 637-648
506
Lawrence Corey, M Juliana McElrath. (2010) HIV vaccines: mosaic approach to virus diversity. Nature Medicine 16:3, 268-270
507
John R. Mascola, David C. Montefiori. (2010) The Role of Antibodies in HIV Vaccines. Annual Review of Immunology 28:1, 413-444
508
Stephanie Planque, Maria Salas, Yukie Mitsuda, Marcin Sienczyk, Miguel A Escobar, Jason P Mooney, Mary-Kate Morris, Yasuhiro Nishiyama, Dipanjan Ghosh, Amit Kumar, Feng Gao, Carl V Hanson, Sudhir Paul. (2010) Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120–CD4-binding site from long-term survivors of HIV infection. AIDS 24:6, 875-884
509
Linda L. Baum. (2010) Role of Humoral Immunity in Host Defense Against HIV. Current HIV/AIDS Reports 7:1, 11-18
510
Andreas Brave, Ulrika Johansson, David Hallengärd, Shirin Heidari, Hanna Gullberg, Britta Wahren, Jorma Hinkula, Anna-Lena Spetz. (2010) Induction of HIV-1-specific cellular and humoral immune responses following immunization with HIV-DNA adjuvanted with activated apoptotic lymphocytes. Vaccine 28:9, 2080-2087
511
Koen K.A. Van Rompay, Kristina Abel, Patricia Earl, Pamela A. Kozlowski, Juliet Easlick, Joseph Moore, Linda Buonocore-Buzzelli, Kimberli A. Schmidt, Robert L. Wilson, Ian Simon, Bernard Moss, Nina Rose, John Rose, Marta L. Marthas. (2010) Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: Attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV. Vaccine 28:6, 1481-1492
512
Duk-Jae Han, David B. Weiner, Jeong-Im Sin. (2010) DNA Vaccines against Infectious Diseases and Cancer. Biomolecules and Therapeutics 18:1, 1-15
513
A. Bansal, J. Carlson, J. Yan, O. T. Akinsiku, M. Schaefer, S. Sabbaj, A. Bet, D. N. Levy, S. Heath, J. Tang, R. A. Kaslow, B. D. Walker, T. Ndung'u, P. J. Goulder, D. Heckerman, E. Hunter, P. A. Goepfert. (2010) CD8 T cell response and evolutionary pressure to HIV-1 cryptic epitopes derived from antisense transcription. Journal of Experimental Medicine 207:1, 51-59
514
J. G. Garcia-Lerma, M.-e. Cong, J. Mitchell, A. S. Youngpairoj, Q. Zheng, S. Masciotra, A. Martin, Z. Kuklenyik, A. Holder, J. Lipscomb, C.-P. Pau, J. R. Barr, D. L. Hanson, R. Otten, L. Paxton, T. M. Folks, W. Heneine. (2010) Intermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV Infection. Science Translational Medicine 2:14, 14ra4-14ra4
515
Ingrid T. Katz, Norma C. Ware, Glenda Gray, Jessica E. Haberer, Claude A. Mellins, David R. Bangsberg. (2010) Scaling up human papillomavirus vaccination: a conceptual framework of vaccine adherence. Sexual Health 7:3, 279
516
Damien V. Cordery, David A. Cooper. (2010) Clinical research in NSW: its role in HIV care and prevention. New South Wales Public Health Bulletin 21:4, 93
517
Peter A. Newman, Surachet Roungprakhon, Suchon Tepjan, Suzy Yim. (2010) Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine 28:4, 958-964
518
Richard A. Koup, Barney S. Graham, Daniel C. Douek. (2010) The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nature Reviews Immunology 11:1, 65-70
519
S. Dhanireddy, R. Harrington. Human Immunodeficiency Virus Infection and the Acquired Immunodeficiency Syndrome. In: Atlas of Sexually Transmitted Diseases and AIDS. Elsevier, 2010:256-286.
520
José A. Esté, Tomas Cihlar. (2010) Current status and challenges of antiretroviral research and therapy. Antiviral Research 85:1, 25-33
521
Dolin , Raphael , . (2009) HIV Vaccine Trial Results — An Opening for Further Research. New England Journal of Medicine 361:23, 2279-2280
Free Full Text522
N. L. Letvin. (2009) Moving Forward in HIV Vaccine Development. Science 326:5957, 1196-1198
523
Kuan-Teh Jeang, Li-Min Huang. (2009) HIV-1 Vaccine—Many Miles to Go Before We Sleep. Journal of the Formosan Medical Association 108:11, 827-829
